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Abstract 
 
Respiratory tract infections (RTI) are major causes of morbidity and mortality, 
with lower respiratory infections alone being the fourth major cause of death in the 
world, taking the life of over 3 million individuals in 2016 (World Health Organization 
(WHO), 2018). Bacterial infections are a major cause of RTI. In this dissertation we 
focused on a subject group who is at high risk of developing severe illness due to 
opportunistic bacterial infections, hematopoietic stem cell transplant (HSCT) patients. 
HSCT utilizes stem cells derived from bone marrow, umbilical cord blood, or peripheral 
blood of patients themselves (autologous) or matched donors (allogeneic) to treat or 
cure a variety of hematological and inherited disorders. This procedure has become 
standard of care with more than 18,000 HSCTs performed every year in the United 
States alone. Unfortunately, patients that undergo HSCT (both autologous and 
allogeneic) are immunosuppressed and remain so even after stem cell engraftment, 
making them susceptible to infections by a wide array of opportunistic pathogens. 
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that can cause 
life-threatening complications in HSCT patients and has recently been identified by the 
WHO as a critical pathogen for which new therapeutic strategies are needed. In the 
lung of immunosuppressed individuals, P. aeruginosa can cause lethal organ injury 
mainly by stimulating alveolar macrophages to secrete high levels of Interleukin-1β (IL- 
1β). IL-1β is a potent pro-inflammatory cytokine that is mainly activated by the serine 
protease caspase-1, but can be activated by caspase-8. Here, we aimed to understand 
xiv  
the reasons behind the success of P. aeruginosa infections in HSCT subjects with the 
use of murine bone marrow transplantation (BMT) model. We identified that high levels 
of prostaglandin E2 (PGE2), a cyclooxygenase (COX) lipid metabolite with hormone-like 
characteristics and found at elevated levels in HSCT patients, induces exacerbated 
levels of IL-1β in HSCT subjects leading to severe lung injury post-P. aeruginosa 
infection. We identified that the PGE2-mediated increase in IL-1β is dependent on 
adenyl cyclase (AC) activation by EP2 and/or EP4 receptor stimulation which leads to 
activation of the transcription factor CREB. We hypothesized that reducing the levels of 
PGE2 in BMT mice can reduce IL-1β-mediated acute lung injury and improve outcome. 
In accordance with our hypothesis, we were able to decrease IL-1β levels, improve 
bacterial killing, and reduce lung injury by treating HSCT mice with indomethacin, a non- 
selective inhibitor of the two isoforms of COX (COX1 & COX2), post-P. aeruginosa 
infection. Additionally, we showed how PGE2 production impaired neutrophil 
extracellular trap (NETs), an important antimicrobial pathway, release post-HSCT in 
human and mouse neutrophils which could implicate immunosuppression to multiple 
microbes including bacterial pathogens. Our findings suggest new therapeutic strategies 
aimed at blocking PGE2 production or signaling may have positive impacts against 
bacterial infections in HSCT subjects. The appendix of this dissertation contains an 
additional chapter looking at influenza-induced immunosuppression of lung innate 
immunity and describes a novel role for toll like receptor 9 signaling in regulating 
secondary bacterial infection post-influenza. 
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Chapter 1. Introduction 
 
1.1 Hematopoietic stem cell transplant (HSCT) 
 
HSCT utilizes stem cells from bone marrow, umbilical cord blood, or peripheral 
blood to treat or cure a variety of malignant disorders such as acute myeloid leukemia 
as well as non-malignant disorders including autoimmune diseases, and sickle cell 
anemia1, 2. Patients that undergo HSCT are first exposed to myeloablative or non- 
myeloablative conditioning followed by infusion of stem cells which can come from 
autologous (same individual), allogeneic (different individual, but compatible human 
leukocyte antigen), or syngeneic (genetically identical individual such as a twin sibling) 
sources. The conditioning regimen is usually high dose chemotherapy, total body 
irradiation and/or a combination of the two. This procedure has become a standard of 
care with more than 60,000 HSCT performed in 2012 worldwide, in which 47% were 
allogeneic and 53% of them where autologous3-5. Although HSCT can be a cure for 
multiple disorders, unfortunately HSCT patients are at high risk of post-transplant 
complications due to immunosuppression and treatment-related toxicity4, 6, 7. Thus, 
better therapeutic strategies are needed to supplement HSCT to improve the outcome 
for patients. Apart from disease relapse, the major post-transplant clinical problems are 
infectious and non-infectious pulmonary complications. 
2 
 
1.2 Non-infectious complications post-HSCT 
 
Pulmonary complications are common post-HSCT and affect around 40%-60% of 
recipients and follow a predictable timeline7. The timeline is divided in three phases. 
Phase 1 is the pre-engraftment period (0-30 days post-HSCT), and it is characterized by 
neutropenia. Phase 2 is the post-engraftment period (30-100 days post-HSCT), and it is 
characterized by impaired cellular immunity. Phase 3 is the late phase (≥100 days post- 
HSCT) and it is characterized by impaired humoral and cellular immunity8. Non- 
infectious complications can be present in any of the phases and are a significant cause 
of morbidity and mortality post-HSCT. The most common non-infectious early 
pulmonary complication is Idiopathic Pneumonia Syndrome (IPS) which occurs in the 
pre-engraftment or early post-engraftment period. IPS is characterized by pulmonary 
edema, alveolar injury, acute pulmonary dysfunction, and cardiac or renal disease, and 
is believed to be caused by the toxicity of chemotherapy and radiation7, 9. Another early 
complication present in HSCT patients is acute graft versus host disease (GVHD) which 
can manifest in the pre-engraftment and post-engraftment period and it is described as 
an immune reaction of donor cells to the host tissue. GVHD is the result of HLA 
mismatch and thus is a complication just seen in allogeneic HSCT and not in 
autologous HSCT patients. Chronic GVHD is the most common late complication and 
can lead to the development of Bronchiolitis Obliterans (BOS), defined by airway 
obstruction, and characterized by bronchiolar fibrosis. Mortality caused by BOS post- 
HSCT is around 12%-27%7, 10, 11. The study of non-infectious complications has been 
well described elsewhere7, 11-14. In this dissertation, I will focus on infectious 
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complications post-HSCT which are also a significant cause of morbidity and mortality 
post-HSCT. 
1.3 Infectious complications post-HSCT 
 
The incidence of infectious complications post-HSCT can be influenced by 
multiple variables including type of transplant (allogeneic or autologous) as well as 
intensity of conditioning 8. Despite the use of antibiotics and other prophylactic 
strategies, pneumonia remains the leading infectious cause of mortality post-HSCT. 
Infectious complications are generally found to be more common in allogeneic 
transplantation rather than autologous procedures as patients are administered 
immunosuppressive drugs to prevent or treat GVHD leading to susceptibility to 
opportunistic pathogens. However, infections are also problematic for autologous 
HSCT patients. For example, one study reported that infectious complications 
contributed to 21% of deaths in autologous transplants compared to 17% of deaths in 
allogeneic transplant patients 6. In another study, autologous patients showed a14% 
incidence for infection15. Thus, both autologous and allogeneic HSCT transplant 
patients are at risk of infectious complications. Infections can occur with bacterial, viral, 
and fungal pathogens; but bacterial pathogens have the higher cumulative incidence15. 
Bacterial infections can occur at any time in the post-transplantation period, but they are 
detected with more frequency in the early phase of neutropenia with a reported 20% to 
50% incidence16, 17. Success in infection by opportunistic bacterial pathogens is 
attributed to damage of the mucosal barrier by conditioning, neutropenia, and 
compromise of the immune system. Gram negative bacteria such as Pseudomonas 
aeruginosa and Klebsiella pneumoniae infections predominate early post-transplant, 
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whereas Gram positive bacteria including Streptococcus pneumoniae predominates in 
the late phase18. Reports have shown that bacterial infections post-transplant can be 
seen in over 51% of patients with 61% of infections coming from Gram negative 
bacteria and 39% from Gram positive6. Antibiotics including ciprofloxacin, penicillin, and 
aminoglycosides are routinely given to HSCT patients. However, many of the successful 
colonizers, including P.aeruginosa and Staphylococcus aureus, are known to be 
resistant to a wide array of antibiotics. Thus, better therapeutic strategies that are 
different than antibiotic usage are needed. 
Viral and fungal infections are also a main cause of post-HSCT infectious complications. 
Cytomegalovirus (CMV) and community acquired respiratory viruses including 
respiratory syncytial virus (RSV), influenza A and B, and parainfluenza are among the 
main viral opportunistic pathogens post-HSCT8. RSV is the most common isolated viral 
pathogen19. Around 11% of HSCT patients develop viral pneumonia. Aspergillus spp 
are the most common fungal pathogens isolated from HSCT patients, with invasive 
pulmonary aspergillosis being the most common invasive fungal infection. Allogeneic 
recipients have a reported incidence of 5%-30%, whereas autologous recipients have a 
1%-5% incidence of pulmonary aspergillosis 20. Other fungal pathogens from Fusarium 
and Scedosporium genera can also cause pulmonary infections post-HSCT8. 
Additionally, patients treated with immunosuppressive therapy due to chronic GVHD are 
at high risk of developing pneumonia mediated by Pneumocystis jiroveci8. Thus, 
infectious complications post-HSCT can occur from bacterial, viral, and fungal 
pathogens. Herein, I will focus on bacterial infections post-HSCT, and will use a mouse 
model to experimentally describe post-transplant infections. 
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Figure 1-1: Murine Bone Marrow Transplantation Model. C57BL/6J mice are irradiated with a split dose of 13Gy. Irradiated mice are 
then infused with 5x106 bone marrow cells from a genetically identical (C57BL/6J) or unrelated (BALB/c) donor. Mice are then housed 
for 5 weeks after bone marrow infusion to achieve full reconstitution of their immune system. 
 
1.4 Animal model to study post-HSCT infections 
 
A murine bone marrow transplantation (BMT) model (Figure 1-1) is used to study 
infectious complications post-HSCT. In this model, mice are exposed to myeloablative 
conditioning before infusion with bone marrow stem cells from a genetically identical 
(syngeneic) or an unlike donor (allogeneic). Total body irradiation with a split dose of 
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13Gy is often used as a conditioning regimen, followed by infusion of 5x106 bone 
marrow stem cells. Mice are then housed for up to 5 weeks for immune cell 
reconstitution. After immune reconstitution around 83% of the alveolar macrophages 
and 94% spleen cells in the recipient mice are donor derived in syngeneic transplants 
21. This mouse model is used to mimic pulmonary immunosuppression to bacterial 
infections as seen in humans post-HSCT22-24. 
1.5 Prostaglandin E2 (PGE2) in HSCT patients 
 
As mentioned earlier, immunosuppressant drugs given to HSCT patients to 
prevent or treat pathologies such as GVHD can increase susceptibility to infections8. 
However, even in the absence of immunosuppressant drugs and in the late phase of 
transplantation, patients remain susceptible to pathogens. In search for an explanation, 
in the early 90’s, an article was published noting that HSCT patients had elevated levels 
of prostaglandin E2 (PGE2)25. This was seen in 100% of the patients and it was 
independent of their conditioning regimen25. PGE2 is a lipid molecule secreted by all 
cells and has been known to have multiple immunosuppressant roles against bacterial, 
viral, and fungal pathogens26. Thus, this article opened the door to explore a possible 
role for an endogenous molecule that might be inducing susceptibility against a wide 
array of opportunistic pathogens post-HSCT. Interestingly, my mouse model of BMT 
has previously been shown to also have elevated levels of PGE2 in the bronchoalveolar 
lavage fluid (BALF) and in whole lung homogenates when compared to non-BMT 
mice27. Elevated levels of PGE2 were shown to have a negative effect in bacterial 
clearance and morbidity, and suppression of PGE2 was shown to improve P. 
aeruginosa infection28, 29. Reasons behind elevation of PGE2 post-HSCT are unknown 
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but, in one study, were attributed to hypomethylation of the COX-2 gene responsible for 
processing of PGE230. Thus, in the absence of immunosuppressant drugs, elevated 
levels of PGE2 in HSCT patients may be inducing susceptibility to infections. 
1.6 PGE2 synthesis 
 
PGE2 belongs to the family of eicosanoids which are lipid hormone-like signaling 
molecules that have important roles in inflammatory and physiological functions 31. 
Homeostatic levels of eicosanoids are always present in mammalian tissue and 
dysregulation of these levels can have different physiological outcomes31, 32. All 
eicosanoid molecules are produced from the enzymatic modification of arachidonic acid 
(AA), a polyunsaturated fatty acid esterified in membrane phospholipids of mammalian 
cells33. Metabolism of AA is mediated by a cascade of events starting by being released 
from cellular membranes by phospholipase A2 (PLA2) enzymes31, 32. Three PLA2 
enzymes can mediate this process, cytosolic calcium-dependent PLA2 (cPLA2), 
cytosolic calcium-independent (iPLA2), and secreted PLA2 (sPLA2)34. The iPLA2 enzyme 
is in charge of maintaining homeostatic levels of free AA, whereas cPLA2 and sPLA2 are 
activated by various stimuli (e.g. microbial recognition)31, 35-37. Membrane liberated AA 
can then be further modified to produce prostaglandins or leukotrienes32 (Figure 1-2). 
For prostaglandin synthesis, free AA is oxidized by one of the cyclooxygenase (COX) 
enzymes, COX-1 or COX-2.37 The COX enzymes are structurally equivalent and are 
around 60% homologous at the amino acid level38. Yet, while COX-1 is constitutively 
expressed in most mammalian cells producing homeostatic levels of prostaglandins, 
COX-2 is inducibly expressed by different stimuli and its expression is highly restricted 
39. The enzymatic action of COX on AA is twofold; first it oxidizes AA to form 
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Figure 1-2: Prostaglandin and leukotriene synthesis. Phospholipases release arachidonic acid (AA) from the phospholipid membrane. Free AA can 
then be modified by the cyclooxygenase or the lipoxygenase pathway to produce prostaglandins and leukotrienes, respectively. During the 
cyclooxygenase pathway, to the left, COX enzymes modify AA to produce PGH2, which can then be modified by specific enzymes to produce PGI2, 
TXA2, PGD2, PGE2, and PGF2α. COX enzymes can be blocked by the nonsteroidal anti-inflammatory drugs, indomethacin and aspirin. 
Prostaglandins are known inhibitors of the antimicrobial function of both macrophages (Mϕ) and polymorphonuclear leukocytes (PMN). The 
lipoxygenase pathway, to the right, leads to the production of LTA4 which can then be modified by specific enzymes to produce LTB4 or LTE4. 
Leukotrienes are known to promote Mϕ and PMN antimicrobial functions. 
 
prostaglandin G2 (PGG2), secondly COX reduces PGG2 to form prostaglandin H2 
(PGH2). Dependent on specific enzymes, PGH2 can be modified to produce 5 known 
different prostaglandins known as prostaglandin D2, prostaglandin I2, thromboxane A2, 
prostaglandin F2α, and PGE2 31, 40, 41. Alternatively, if AA is metabolized via the actions 
Cellular Membrane Phospholipids 
Phospholipase 
 
Arachidonic Acid (AA) 
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of 5-lipoxygenase and 5-lipoxygenase activating protein, ultimately leukotriene 
synthesis can occur42. In terms of innate immunity there is an intricate “yin and yang” in 
regulation of innate immune cell function via the actions of prostaglandins versus 
leukotrienes with prostaglandins generally inhibiting the functions of macrophages and 
neutrophils whereas leukotrienes can promote function of these cells 43. 
PGE2 synthesis is mediated by 3 different enzymes termed: cytosolic PGE synthase 
(cPGES), microsomal PGE synthase-1 (mPGES-1), and microsomal PGES-2 (mPGES- 
2). It is known that physiological levels of PGE2 are maintained by the enzymatic action 
of cPGES and mPGES-2, whereas mPGES-1 is activated by a wide array of stimuli 
including pathogen recognition. Upon intracellular production, PGE2 is secreted to the 
extracellular compartment by the multidrug resistance protein 4 channel44. 
Extracellularly, PGE2 can signal through 4 different G-protein coupled receptors 
(GPCRs) or it can be rapidly degraded by 15-hydroxyprostaglandin dehydrogenase to 
an inactive metabolite termed 15-keto prostaglandin E2 45 (Figure 1-3). Interestingly, 
dysregulation of PGE2 has been implicated to play a role in many disease outcomes, 
including diabetes and cancer32, 45-47. The full spectrum of its role as an inflammatory 
mediator is still unknown as both pro- and anti-inflammatory roles have been shown. 
For example, PGE2 can mediate endothelial permeability to promote inflammatory cell 
recruitment48; yet actions on inflammatory cells themselves are often inhibitory as 
described below. PGE2 can signal through 4 different PGE2 receptors which are known 
as E type prostanoid or EP receptors, which might explain the multiple reported 
functions. 
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1.7 PGE2 signaling 
 
PGE2 effector functions have been shown to modulate many biological processes 
including cell proliferation, apoptosis, angiogenesis, inflammation, and immune 
surveillance. This is due to the ability of PGE2 to signal in both autocrine and paracrine 
manners through four different types of EP GPCRs, namely EP1, EP2, EP3, and EP4 31, 
38, 40, 45, 49. EP receptors differ in their intracellular signaling pathways, affinity to PGE2, 
as well as tissue and cellular localization. EP signal transduction pathways have been 
an important topic of study in host defense against microbial pathogens 34, 50. 
In humans and rats, the EP1 receptor has the lowest affinity for PGE2 among all EP 
receptors 51, whereas in mice, it is the second lowest affinity. It is coupled to a Gq alpha 
subunit (Gαq), which activates the phospholipase C pathway leading to an increase in 
intracellular Ca2+ levels by activation of Ca2+ protein channels and subsequently 
activation of protein kinase C (PKC)52. Signal transduction mediated by PKC leads to 
the activation of mitogen-activated protein kinases (MAPK) which are essential in 
inducing an immune response against viral infections53, 54. PKC also leads to the 
activation of the transcription factors NFAT and NFκB. Dysfunction of the EP1 receptor 
results in decreased colon tumorigenesis in models of chemically-induced colon cancer 
in mice, suggesting an important role of this receptor and PGE2 in inflammation-induced 
cancer 45. EP1 has not been shown to play major roles in innate immunity, but it can be 
an important facilitator of naïve T cell differentiation, particularly to suboptimal stimuli55, 
56. 
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The EP2 and EP4 receptors mediate most of the immunomodulatory effects of PGE2 in 
innate and adaptive immune cells. EP2 and EP4 are coupled to the Gs alpha subunit 
(Gαs) and activation of these receptors leads to increased cyclic adenosine 
monophosphate (cAMP) mediated by adenylate cyclase activation 40. EP4 has a higher 
affinity for PGE2 compared to EP2. However, EP2 can increase cAMP levels to a higher 
degree than EP4 stimulation; which is believed to be caused by a faster desensitization 
of the EP4 receptor 40. Increased intracellular cAMP leads to activation of protein kinase 
A (PKA) and its sister molecule, the exchange protein directly activated by cAMP 
(EPAC), which activates the transcription factor CREB 57. In addition to CREB 
activation, EP2 and EP4 signaling can lead to inhibition of glycogen synthase kinase-3 
(GSK-3) which inhibits the translocation of β-catenin into the nucleus. Interestingly, 
inhibition of GSK-3 by EP2 is dependent on increased levels of cAMP, whereas EP4- 
mediated inhibition of GSK-3 is independent of cAMP and dependent on activation of 
phosphatidylinositol 3-kinase (PI3K)40. The ability of EP4 to directly activate PI3K upon 
PGE2 binding also leads to the activation of the extracellular signal-regulated kinases 
(ERKs) that activate early growth response factor-1 which can control the expression of 
many genes including tumor necrosis factor (TNF)-α, COX-2, and mPGES140. EP2 and 
EP4 signaling have also been shown to increase the levels of interleukin-10 (IL-10) 
while decreasing the levels of TNF-α 58, 59.  The fact that EP2 and EP4 can both 
activate cAMP, but that they also differ in downstream signaling likely explains why 
these receptors have been shown to have both similar and divergent roles depending 
on the infection as discussed in greater detail below. 
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Figure 1-3: Prostaglandin E2 signaling. PGE2 can signal through 4 different GPCR subtypes termed EP1-4 or can 
get degraded to its inactive metabolite, 14-Keto-PGE2. The EP1 receptor is coupled to the Gaq subunit which leads 
to the increase of intracellular Ca2+ levels. EP2 and EP4 are coupled to Gas while EP3 can couple to Gi, Gαs or 
G12/13. EP1 is known to induce NFkB and NFAT transcription factors, while EP2 and EP4 can induce NFkB and 
CREB. When EP3 is coupled to Gas, it can induce NFkB/CREB, but when coupled to Gi, it can inhibit these factors. 
Figure created using ScienceSlides 
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EP3 is the only EP receptor that exists in multiple variants (α, β, and γ) that are 
generated by alternative splicing of the carboxyl terminal tail38, 60. These variants of the 
EP3 receptor have equal affinity for PGE2, yet they differ in their signal transduction, 
desensitization, and relative expression. The three isoforms of EP3 can inhibit the 
activation of cAMP when coupled to the Gi protein subunit, which can also increase the 
levels of intracellular Ca2+ and can result in the antagonism of PGE2 signaling via EP2 
and/or EP4. Alternatively, EP3 can also bind to Gαs and G12/13, meaning that in some 
instances EP3 signaling can mimic EP2 or EP4 elevations of cAMP 61, 62. Figure 1-3 
summarizes the downstream signaling associated with each of the EP receptors. 
1.8 The role of PGE2 in bacterial infection 
 
PGE2 signaling can also impair immunity to viral and fungal pathogens, yet, for 
the purpose of this dissertation work, I will focus just on the role of PGE2 in bacterial 
infections and its implication in HSCT individuals. The role of PGE2 in host defense 
against multiple bacterial infections has been well described elsewhere 34. Thus, in this 
dissertation, I will restrict my focus on how PGE2 regulates infection to some of the 
microbes that present complications to HSCT patients and that are also on the World 
Health Organization’s (WHO, 2017) list of the most critical bacterial pathogens 
impacting human health which includes Mycobacterium tuberculosis, Pseudomonas 
aeruginosa, Streptococcus pneumoniae, and Staphylococcus aureus. As noted below, 
the impact of PGE2 on these infections is not uniform. 
Mycobacterium tuberculosis (MTb) is an intracellular bacterium and the causative agent 
of tuberculosis, which killed 1.8 million infected individuals in 2015 and according to the 
WHO has surpassed human immunodeficiency virus (HIV) as the leading cause of 
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death due to a single infectious agent. MTb, in any phase post-transplant, can cause 
complications post-HSCT6. In response to MTb infection, macrophages produce high 
levels of PGE2 partially mediated by activation of the TLR2/p38 MAPK signaling 
pathway and the nuclear receptor PPARγ 63-65. Despite the fact that PGE2 is known to 
inhibit phagocytosis and killing of many bacterial pathogens by macrophages 24, 66, 
increased production of PGE2 and signaling through the EP2 receptor is protective 
against MTb and EP2-/- mice are more susceptible to infection, compared to wildtype 
mice 67. However, these protective effects are more closely aligned with adaptive 
immune alterations than innate immune signaling which is not surprising given that MTb 
replicates intracellularly. EP2 signaling was necessary to mount antigen-specific 
immunity and to downregulate the number of T regulatory cells which can dampen 
effector T cell responses67. PGE2 inhibition by indomethacin reduces MTb specific TH1 
cells upon MTb infection, suggesting that PGE2 signaling is necessary to generate MTb 
specific adaptive immunity68. In addition, indomethacin treatment has been shown to 
activate the DP2 receptor in Th2 cells leading to higher levels of IL-2 and IL-5, which 
could also influence Mtb responses independent of PGE2 levels69. Furthermore, genetic 
polymorphism of EP2 in humans is correlated with susceptibility to MTb infection, as 
shown by a study of healthy and infected individuals from a large Chinese Han 
population 70. Infection with a virulent strain of MTb leads to decreased PGE2 and high 
lipoxin A4 leading to successful spread of the pathogen by induction of macrophage 
necrosis, whereas high levels of PGE2 leads to control of infection by induction of 
apoptosis 71-73. A shift towards necrosis within alveolar macrophages as a result of 
decreased levels of PGE2 post-MTb was dependent on the virulence factor, 
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phospholipase C 74. Interestingly, the role of PGE2 in MTb infections also seems to be 
dependent on the stage of infection. During acute infection, COX-2 inhibition leads to a 
successful pathogen colonization of the lung, whereas an inhibition of COX-2 during 
chronic infection leads to improved clearance of MTb 34, 75. 
Pseudomonas aeruginosa is an extracellular Gram-negative, multi-drug resistant, 
opportunistic bacterial pathogen that infects immunocompromised individuals including 
cystic fibrosis patients and HSCT patients 22, 76. In contrast to the effects of PGE2 to 
promote clearance of intracellular MTb, elevated levels of PGE2 in the lungs of HSCT 
patients or bone marrow transplant (BMT) mice are known to enhance susceptibility of 
the host to P. aeruginosa infection 22. Conditioning of the host by either total body 
irradiation or chemotherapy can cause elevations of PGE2 21, 25. In the mouse, one 
mechanism that has been identified is that lung epithelial cells release transforming 
growth factor beta (TGFβ) in response to total body irradiation. In turn, the TGFβ binds 
to receptors on alveolar macrophages to upregulate a miRNA known as miR29b which 
then destabilizes the mRNA for DNA methyltransferase enzymes 77. In the absence of 
DNA methyltransferases, the COX-2 gene becomes hypomethylated and 
overexpressed promoting the production of PGE2 post-BMT 77. In addition to the 
elevations of PGE2 by BMT alone, P. aeruginosa infection can cause macrophages to 
increase PGE2 secretion by activation of phospholipase A2α (PA2α) 78. PGE2 signaling 
via the cAMP-coupled EP2 or EP4 receptors leads to activation of IRAK-M and 
phosphatase and tensin homolog on chromosome 10 (PTEN) impairing phagocytosis 
and P. aeruginosa killing, as well as suppressing production of TNF-α and cysteinyl 
leukotrienes 79, 80. BMT mice are more susceptible to P. aeruginosa infection unless 
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transplantation has been done with stem cells from either IRAK-M-/-  and/or PTEN-/- 
mice, suggesting that inhibition of IRAK-M and PTEN are potential therapeutic targets to 
improve P. aeruginosa clearance post-BMT. In addition, improved clearance of P. 
aeruginosa in the lungs of BMT mice has been achieved by indomethacin treatment 
which blocks COX function and reduces PGE2 levels post-transplant 81. PGE2 has also 
been shown to downregulate the scavenger macrophage receptor MARCO, which is the 
receptor necessary for recognition of non-opsonized P. aeruginosa 24. Thus, P. 
aeruginosa-induced PA2α activation with subsequent secretion of PGE2 is a mechanism 
that confers successful colonization with P. aeruginosa in normal hosts. Moreover, in 
BMT hosts which have elevations of PGE2 in the lungs constitutively, infection with P. 
aeruginosa is particularly deadly82. 
Streptococcus pneumoniae is a Gram-positive facultative anaerobic bacterium that is 
responsible for the majority of community-acquired pneumonia and is the main bacterial 
pathogen inducing mortality in influenza-associated secondary infections83. S. 
pneumoniae causes complications post-HSCT in the late phase post-transplant18. Upon 
S. pneumoniae lung infection, alveolar type II cells upregulate COX-2, secreting high 
levels of PGE2 that signal mainly through the EP4 receptors on lung macrophages 84. 
Additionally, neutrophils secrete high amounts of PGE2 and LTB4 upon exposure to S. 
pneumoniae’s virulence factor, pneumolysin 85. Signaling through EP4 receptors in 
alveolar macrophages post-S. pneumoniae infection was shown to decrease the levels 
of S. pneumoniae-induced cytokines such as TNF-α 86. Moreover, PGE2 has been 
shown to play a pivotal role in efferocytosis (apoptotic cell removal) by alveolar 
macrophages. High levels of PGE2-mediated by uptake of apoptotic bodies compromise 
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the immune response to S. pneumoniae by decreasing phagocytosis, bacterial killing, 
and H2O2 production dependent on EP2/EP4 activation of cAMP 87, 88. Mice deficient in 
EP2 or treated with indomethacin have improved killing and survival post-S. 
pneumoniae lung infection 89, 90. Interestingly, EP3-deficient mice also have improved 
bacterial clearance, phagocytosis and survival post-S. pneumoniae infection 91. The 
reason for EP3 to influence S. pneumoniae killing was linked to higher production of 
nitric oxide (NO) by the EP3-/- alveolar macrophages and one possible explanation for 
this was that the unchecked signaling of PGE2 via the remaining EP2 and EP4 
receptors might explain this phenomenon 91. Additionally, since the EP3γ receptor 
isoform has been shown to also activate adenylate cyclase in overexpression studies 61, 
62, 92, this may be the reason EP3-deficient mice experience improved survival and 
bacterial clearance post-S. pneumoniae lung infection, compared to wildtype mice even 
though their febrile response was blunted 91. 
In contrast to these studies which suggest PGE2 limits host defense against S. 
pneumoniae, one study evaluating genetic ablation of mPGES-1 with subsequent 
reduction of PGE2 showed higher bacterial burden, decreased mouse survival, lower 
expression of NADPH oxidase and lower NO production post- S. pneumoniae infection 
93. It is not immediately clear how to reconcile these differences, but one possibility is 
that selective targeting of mPGES-1 caused a redistribution of eicosanoid synthesis that 
is not fully characterized that may have impacted outcomes. Therefore, the role of 
PGE2 in host defense against S. pneumoniae is complex, yet the majority of evidence 
suggests a negative role of PGE2 on S. pneumoniae clearance. 
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Staphylococcus aureus is a Gram positive, biofilm-producing bacterium that has 
acquired antibiotic resistance to multiple drugs making it one of the leaders of 
nosocomial infections. Like other Gram positive bacteria, S. aureus causes 
complications to HSCT patients in the post-engraftment and late phase periods18. S. 
aureus’s lipoteichoic acid is a known inducer of COX-2 expression and PGE2 signaling 
94-97. S. aureus-mediated activation of COX-2/PGE2 pathway in oral epithelial cells 
facilitates S. aureus’s growth and biofilm production improving bacterial attachment to 
fibronectin 94. In addition, the synergistic interaction between the fungal pathogen 
Candida albicans and S. aureus is mediated by increased PGE2 caused by C. albicans 
infections, inducing improved biofilm formation of S. aureus 98. Thus, S. aureus 
induction of PGE2 leads to improved growth and survival of the bacteria at the early 
stages of infection. However, PGE2 is also a well-known inducer of TH17 immunity, 
which is necessary to clear S. aureus infections. One study showed that diabetic mice 
have low levels of PGE2 leading to low TH17 immunity and high susceptibility to S. 
aureus infections 99. Thus, inhibition of PGE2 at the early stages of infection might 
improve S. aureus clearance, whereas at the late stages in might be beneficial to 
stimulate PGE2 synthesis to increase IL-17 and improve survival in chronic infections. 
In addition to the pathogens discussed here, virulence factors of enteric pathogens 
including Salmonella serotypes (S.enterica, S.dublin, and S.typhimirium), Escherichia 
coli, and Vibrio cholerae are well-known inducers of PGE2 as a means of establishing 
infection and limiting host defense 34. A successful infection of Salmonella depends on 
the induction of COX-2 expression by ERK1/2 activation and inhibition of COX-2 leads 
to better killing of intracellular Salmonella in infected macrophages 100. Furthermore, in a 
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model of sepsis induced by lethal administration of E.coli’s LPS, COX-2-/- mice have 
shown improved survival compared to wild-type mice 101. Thus PGE2 plays an essential 
regulatory role in bacterial defense to a wide array of pathogens. Overall, PGE2 seems 
to promote growth of extracellular bacterial species by limiting host innate immune 
responses. In contrast, PGE2 impairs adaptive immune responses needed to clear 
intracellular MTb. 
1.9 Rationale for this dissertation 
 
This dissertation research work is focused on the impact that PGE2 has on 
immunity to bacterial pathogens in the context of HSCT. As mentioned before, there are 
more than 60,000 HSCT performed every year as a way to cure multiple diseases. 
However, HSCT patients are at high risk of post-transplant complications, many of them 
caused by opportunistic pathogens. These infections are a significant cause of morbidity 
and mortality post-transplant. This work focuses on the effect of PGE2 in critical 
intracellular pathways known to play a role in immunity to bacterial pathogens, the 
inflammasome and neutrophil extracellular traps (NETs) release. 
1.10 PGE2 and inflammasome-dependent IL-1β secretion 
 
One of the most critical cytokines needed to initiate inflammation and innate 
immune responses is interleukin 1 (IL-1)β which is proteolytically cleaved and activated 
from an immature precursor protein by caspase-1 as part of a multi-protein complex 
known as an inflammasome. Inflammasomes react to pathogenic stimuli leading to the 
activation and secretion of both IL-1β and IL-18. If not properly regulated, overzealous 
inflammasome activation can lead to a form of caspase-1-dependent cell death known 
as, pyroptosis 102. The mechanism of IL-1β secretion by inflammasome activation is 
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known to be dependent primarily on two main signals. Signal 1 is mediated by activation 
of pattern-recognition receptors (PRRs) [e.g. toll like receptors (TLRs) and nod-like 
receptors (NLRs)] by pathogen-associated molecular patterns or PAMPs [e.g. 
lipopolysaccharide (LPS) found in Gram negative bacteria and lipoteichoic acid found in 
Gram positive bacteria)]. PAMP activation of the PRRs increases the levels of mRNA 
and ultimately protein for the intracellular immature IL-1β and IL-18 precursors. Signal 
two is delivered by the recognition of multiple agonists (e.g. adenosine triphosphate or 
bacterial Type III secretion system proteins) leading to inflammasome aggregation and 
caspase-1-dependent processing of IL-1β and IL-18 into their mature forms 103. The 
activation of the inflammasome needs to be highly regulated as low activation might 
lead to a decrease in pathogen clearance and a high activation can lead to the 
development of IL-1β-driven auto-inflammatory syndromes 102. Dysregulation of one of 
the members of the inflammasome family, the NLRP3 inflammasome, has been linked 
to the development of cryopyrin-associated periodic syndrome (CAPS), as well as to 
vascular diseases, non-alcoholic fatty liver diseases, obesity and type II diabetes 104, 105. 
The role of PGE2 on inflammasome and IL-1β activity stills needs to be fully elucidated 
as reports are conflicting. Two groups have reported that elevation of intracellular cAMP 
by PGE2 inhibits the NLRP3 inflammasome, with subsequent decreased IL-1β 
secretion104, 106. Inhibition of the NLRP3 inflammasome by PGE2 was demonstrated to 
be dependent on EP2/4-mediated activation of PKA which was found to phosphorylate 
the Ser295 residue in NLRP3 inhibiting its function 104. Furthermore, this residue is 
found to be mutated in CAPS patients, explaining the over-activation of the NLRP3 
inflammasome in these individuals106. These findings are specific to the NLRP3 
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inflammasome and not to other inflammasome scaffolds. Other studies have shown that 
PGE2 stimulation exacerbates NLRP3 dependent IL-1β secretion in a mouse model of 
scorpion venom infection. These discrepancies in the association of PGE2 with IL-1β 
levels provided the rationale for my studies in Chapter 3 looking more carefully at the 
regulation of IL-1β by PGE2. 
1.11 PGE2 and Neutrophil Extracellular Traps (NETs) formation 
 
Neutrophils are the most abundant leukocyte circulating in the blood and are the 
first recruited cells to the site of infection after tissue sentinel cells encounter pathogens 
107-109. Upon pathogen recognition, neutrophils can kill microbes by phagocytosis, 
degranulation (secretion of antimicrobial molecules), and the release of NETs 110. NETs 
are web-like structures of decondensed chromatin containing the antimicrobial peptides 
neutrophil elastase (NE) and myeloperoxidase (MPO), which can trap and kill 
pathogens 111. This recently described antimicrobial pathway has been shown to play a 
role in the clearance of pathogens that are too big to be engulfed by phagocytosis 
including Candida albicans hyphae and extracellular aggregates of Mycobacterium 
bovis 112. Yet, they can also play a role in killing of smaller bacterial pathogens including 
S. aureus, Salmonella typhimurium, and Shigella flexneri 111. NETs release has been 
shown to be dependent on the scavenger receptor dectin-1, superoxide generation and 
the intracellular pathway known as autophagy which allows for cellular homeostasis 
under periods of stress 113. Inhibition of either autophagy or NADPH oxidase as well as 
dectin-1 deficiency can inhibit the formation of NETs 112, 113. Given that PMNs and 
NETS are likely to play an important role in defending against numerous bacterial and 
fungal pathogens known to infect HSCT patients and knowing that HSCT patients are 
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more susceptible to such infections provided the rationale for why this dissertation 
addressed the question of how HSCT and PGE2 regulate NETs in Chapter 4. 
1.12 Conclusions 
 
HSCT patients are at high risk of post-transplant complications due to 
immunosuppression and treatment-related toxicity. Pulmonary infections, particularly 
bacterial infections, are major complications in HSCT patients and contribute 
significantly to increased morbidity and mortality. HSCT patients have elevated levels of 
PGE2 in the serum and in the BALF. PGE2 has multiple functions on immune cells 
(Figure 1-4) and tends to lend the host more susceptible to bacterial, fungal, and viral 
infections. In this dissertation, the role of PGE2 in regulating immunity to bacterial 
pathogens post-HSCT was studied in alveolar macrophages and PMNs, with a focus on 
the innate intracellular pathways, inflammasome and NETs. 
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Figure 1-4: PGE2 effects on immune cells. (From left to right) Macrophages, dendritic cells, neutrophils and T 
cells. The known effects of PGE2 on these cells are summarized below each cell. Symbol meaning: ↑ 
increase/activation; ↓ decrease; ˧ inhibits. Figure created using ScienceSlides. 
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Chapter 2. 
 
Material and Methods 
 
 
2.1 Human Subjects 
 
Experimental samples were from human subjects that received hematopoietic 
stem cell transplant; patients were from the age of 27-71 at the moment of blood 
collection. Control samples were from healthy volunteers from the age of 23-53 at the 
moment of blood collection. Written informed consent was received and all experiments 
were approved by the University of Michigan institutional review board. 
2.2 Animal 
 
C57BL/6J and BALB/c mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) and bred in the animal facilities at the University of Michigan (Ann Arbor, 
MI). Breeding colonies of TLR9-/- mice, on a BALB/c background, were kindly donated 
by Dr. Shizuo Akira and were also bred in the animal facilities of the University of 
Michigan (Ann Arbor, MI). All mice used were at least 6-7 weeks old by the time of 
infection and/or treatment. Experiments were approved by the University of Michigan 
Institutional Animal Care and Use Committee. 
2.3 Cell culture media 
 
Supplemented media (Complete media) (89% Dulbecco’s Modified Eagle 
Medium (DMEM) (Lonza) without L-Glutamine, 10% Fetal bovine serum (FBS) (Gibco), 
1% Penicillin-streptomycin (Pen-Strep) (Gibco), 2mM L-Glutamine (Gibco), and 
37 
 
250ng/ml Amphotericin (Gibco)); Serum Free media (SFM) (DMEM without L- 
Glutamine, 0.1% Bovine serum albumin (BSA) (Sigma-Aldrich), 1% Pen-Strep, 2mM L- 
Glutamine, and 250ng/ml Amphotericin (Gibco)); Bronchoalveolar lavage media 
(Complete media, and 5mM ethylenediaminetetraacetic acid (EDTA) (Lonza)); L-cell (L- 
929) media (10% FBS, 1% Pen-Strep, 89% Iscove's Modified Dulbecco's Medium with 
4mM L-Glutamine (IMDM) (Hyclone)); Bone Marrow Derive Macrophages (BMDM) 
media (10% FBS, 1% Pen-Strep, 59% IMDM with 4mM L-Glutamine, and 30% L-cell 
supernatant). 
2.4 Reagents 
 
PGE2 (1-1000nM; Cayman Chemicals, Ann Arbor, MI); Forskolin (25μM; Cayman 
Chemical, Ann Arbor, MI); Pseudomonas aeruginosa LPS (100ng/ml; Sigma-Aldrich, St. 
Louis, MO); Adenosine triphosphate (ATP) (1μM; Sigma-Aldrich, St. Louis, MO); 
Caspase-1 inhibitor (10nM Ac-YVAD-CHO; Enzo Life Sciences, Farmingdale, NY); 
Caspase-8 inhibitor (10nM Ac-IETD-CHO; BD Biosciences, San Jose, CA); CREB 
inhibitor (100μM Naphthol AS-E phosphate; Sigma-Aldrich, St. Louis, MO); EP2 agonist 
(1μM Butaprost; Cayman Chemical, Ann Arbor, MI), EP3 agonist (10nM Sulprostone; 
Cayman Chemical, Ann Arbor, MI) EP4 agonist (500nM ONO-AE1-329; Sigma-Aldrich, 
St. Louis, MO); Protein Kinase A (PKA) agonist (50μM 6-BNZ-cAMP; Biolog, Hayward, 
CA); Epac agonist (50μM 8-pcpt-2’-OM-cAMP; Biolog, Hayward, CA). Indomethacin 
(1.2mg/kg; Sigma-Aldrich, St. Louis, MO); Diclofenac (30mg/kg; Sigma-Aldrich, St. 
Louis, MO); PF-04418948 (EP2 antagonist) (10nM; Pfizer); AE3-208 (EP4 antagonist) 
(1μM; Cayman Chemical, Ann Arbor, MI); Rapamycin (1μM; Sigma-Aldrich, St. Louis, 
MO); H-89 dihdrochloride hydrate (PKA antagonist) (20μM; Sigma-Aldrich, St. Louis, 
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MO); ESI-09 (Epac antagonist) (35 μM; Sigma-Aldrich, St. Louis, MO); Wortmannin 
(100nM; Sigma-Aldrich, St. Louis, MO); Diphenyleneiodonium (DPI) (10μM; Sigma- 
Aldrich, St. Louis, MO); Anti-IFN-γ neutralizing antibody (XMG1.2) (200Μg; BioXcell; 
West Lebanon, NH); ODN 2088 and 2088 control (50ug; InvivoGen; San Diego, CA); 
Recombinant mouse IFN-γ (10ng/ml, RD systems; Minneapolis, MN). 
2.5 Isolation of Human Neutrophils 
 
Neutrophils were isolated from human blood by gradient centrifugation. Briefly, 
blood was overlaid gently in Ficoll-Paque (GE healthcare) medium prior to centrifuging 
at 1,400rpm with slow acceleration and no brake for 20min. Neutrophils were then 
separated from the plasma and PBMCs and mixed with 20% dextran for 15min. Solution 
was then diluted with PBS and left undisturbed for 30min. After incubation there are two 
layers, neutrophils are isolated from the top layer, the bottom layer contains the red 
blood cells-Dextran. Solution containing neutrophils was then centrifuged and pellet was 
resuspended in 20mL of 0.2% NaCl for 3min followed by 30mL of 1.8% NaCl to lyse red 
blood cells. Neutrophils were washed, counted, and differential staining was performed 
to detect purity of the assay. 
2.6 Isolating murine neutrophils from lung 
 
Neutrophils were recruited to the lung by administration of 50μl of 
lipopolysaccharide (LPS) (25μg/ml) diluted in saline solution. BAL was performed 18 
hours post-LPS administration with RPMI with L-Glutamine without phenol red (Gibco). 
BALF fluid was centrifuged for 10min at 1,200rpm prior to RBC lysis. Pellets were 
reconstituted in complete media and cells were counted before platting. Differential 
staining was performed to detect purity of the assay. 
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2.7 Isolating murine bone marrow neutrophils 
 
Neutrophils were isolated from the femur and tibia of healthy C57BL/6J mice by 
gradient centrifugation. Briefly, mice were euthanized by CO2 asphyxiation and femur 
and tibia were collected in a sterile environment. Epiphyses of the bones were cut and 
26Gx½ needles were used to flush 10mls of complete media containing 2mM EDTA 
onto a 50ml conical tube. Larger bone marrow tissue was disaggregated by aspirating 
up and down with a syringe containing an 18Gx½ needle. Samples were centrifuged at 
1,400 rpm for 7 min at 4 °C. RBC was lysed with RBC lysis buffer. 1ml of sample was 
added onto a 15ml conical tube containing 3ml of warmed Histopaque 1119 (Sigma- 
Aldrich) below 3ml of Histopaque 1077 (Sigma-Aldrich). Samples were centrifuged for 
30min at 2,000 rpm at 25oC without brake. Neutrophils were collected from the interface 
of the Histopaque 1119 and Histopaque 1077 layers. Neutrophils were washed in PBS, 
counted, and differential staining was performed to detect purity. 
2.8 Isolation of human peripheral monocyte-derived macrophages 
 
Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of 
human blood from healthy volunteers, and then differentiated in vitro with complete 
media containing macrophage colony stimulation factor (M-CSF) (RD systems). Briefly, 
blood was gently overlaid into Ficoll-Paque (GE healthcare) prior to centrifugation at 
1,440 rpm with slow acceleration, and no break at room temperature (25oC) for 20min. 
PBMCs were isolated from the interface of the plasma and Ficoll-Paque. PBMCs were 
washed in PBS and incubated in 175cm2 tissue culture flask in complete media for one 
hour at 37oC with 5%CO2. After an hour, media was aspirated and cells were washed in 
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PBS before incubating for 6-7 days at 37oC with 5%CO2 in complete media containing 
2.5ng/ml of M-CSF. 
2.9 Isolation of murine Alveolar Macrophages (AMs) 
 
AMs are harvested by performing bronchoalveolar lavages (BAL). Briefly, mice 
were euthanized by CO2 asphyxiation, and placed in a sterile foam board prior to 
exposing the chest cavity and trachea. Two washes with 10ml of BAL media were 
performed per mouse where BAL fluid (BALF) was collected in a 10ml sterile syringe 
and transferred onto a 50ml conical. BALF was centrifuged at 1,200rpms for 10mins 
prior to lysing the red blood cell with a RBC lysis buffer. AMs pellet was then dissolved 
in complete media. Each mouse provides around 3x105-5x105 AMs. Thus, multiple mice 
have to be used dependent on the experiments. 
2.10 Isolation of lung macrophages 
 
Total lung cells were obtained by perfusing the lung with PBS followed by 
digesting the whole lung with Collagenase A (Sigma-Aldrich, St. Louis, MO). Lung 
macrophages were selected by adherence selection to a cell culture tissue plate from 
total lung cells that were added for 30min and then washed twice in PBS. Over 90% 
purity was confirmed by differential staining of attached cells. 
2.11 Differentiation of Bone Marrow Derived Macrophages (BMDMs) 
 
BMDMs were differentiated by isolating bone marrow stem cells and incubating 
them with L-cell supernatant. Briefly, mice were euthanized by CO2 asphyxiation and 
femur and tibia were isolated. Epiphyses of the bones were cut and 26Gx½ needles 
were used to flush 10mls of complete media containing 2mM EDTA onto a 50ml conical 
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tube. Cells were centrifuged to remove media at 1,200rpm for 10 minutes in 4oC. Red 
blood cells were then lysed, and bone marrow stem cells were incubated for 7 days on 
BMDMs differentiation media. Every two days media was changed. 
2.12 Bone Marrow Transplantation 
 
Healthy 6-8 week old C57BL/6J male mice were irradiated with a split dose of 13 
gray (13-Gy) with the use of an X-rad 320 irradiator. Irradiated mice were infused with 
5x106 bone marrow cells from a genetically identical donor (C57BL/6J). Mice were 
housed for 5 weeks after infusion to achieve full reconstitution of their immune system. 
The percentage of donor-derived cells was 95 ± 1% in the spleen and 82 ± 2% in the 
lung at this time point, as assessed by transplanting CD45.1+ bone marrow into 
C57BL/6J CD45.2+ mice1. 
2.13 LPS-induced lung injury 
 
Acute lung injury was induced by intratracheal inoculation of 50µg of 
P.aeruginosa-derived LPS (Sigma-Aldrich) in 40µl of saline solution. BALF and lung 
were harvested 24hours after treatment. 
2.14 In vivo influenza infections 
 
All influenza infections were done with the influenza A virus (H1N1) strain 
A/PR/8/34 (PR8) purchased from American Type Culture Collection (ATCC) (Manassas, 
VA). Briefly,  intranasal instillation of 30µl of PBS containing 10-100 plaque forming 
units of PR8 were performed in healthy female or male mice that were anesthetized with 
a mixture of ketamine and xylazine. Mice were monitored daily for weight loss until 
harvest day, usually 5-10 days post-infection. 
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2.15 Viral load quantification in lung by plaque assay 
 
Madin-Darby canine kidney (MDCK) cells were used for the viral titer 
quantification from whole lungs of infected mice. Briefly, 2x105 MDCK cells were grown 
in 12-well plate until well-covered cell monolayer was achieved. Cells were then 
incubated with serial dilutions of homogenized lungs from infected mice. Cells were 
washed in 1x MEM-BSA (DMEM, 2mM L-Glutamine, 250ng/ml amphotericin, Pen-Strep, 
and 10% BSA) medium, then incubated with gentle agitation for an hour at 37oC with 
virus containing sample prior to incubation with a MEM-BSA & 3% Carboxy Methyl 
Cellulose solution. Plates were incubated at 37oC for 48-72 hours before adding a 
crystal violet solution for plaque quantification. 
2.16 In vivo bacterial infections 
 
Lung bacterial infections were done with a non-invasive oral instillation method. 
 
Briefly, mice were anesthetized with a mixture of ketamine and xylazine prior to be 
placed in a sterile foam board where sterile forceps were used to gently pull the tongue 
prior administrating 50μl of PBS-containing bacteria in their oral cavity; nasal air 
passage were close with forceps and mice aspirated the bacteria. Pseudomonas 
aeruginosa (PA01) infections were intended to be at 5x105 CFUs per mouse but 
instillations through all experiments came in the range of 2x105-1x107 CFUs. 
Streptococcus pneumoniae (SPS3)(Serotype 3, 6303) infections were intended to be at 
1x105 CFUs per mouse but instillations through all experiments came in the range of 
1x105-4x105 CFUs. Methicillin-resistant Staphylococcus aureus (MRSA) (NRS384; 
US300) infections were intended to be 7x107CFUs per mouse but instillations through 
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all the experiments came in the range of 5x107-2x108CFUs. Mice were monitored daily 
until harvest day, usually 24-48 hours post-infection. 
2.17 Bacterial burden quantification 
 
Total lung bacterial burden measurements were obtained by performing BAL in 
infected lung before homogenizing the lung in 1ml PBS with a tissue homogenizer 
(OMNI International; Kennesaw, GA). Serial dilutions of BALF and lung were performed 
and plating was done on nutrient agar plates. Plates were incubated for 24 hours at 
37oC prior to counting colonies. Absolute bacterial numbers in the BALF and lung were 
added together and were transformed to logarithmic values for statistical analysis. 
2.18 Viral and bacterial co-infection 
 
Initial influenza infections were performed by intranasal instillation of 30µl of PBS 
containing 100 PFUs of PR8 to mice that were anesthetized with a mixture of ketamine 
and xylazine. Secondary bacterial infection with MRSA 7x107CFUs or SPS3 1x105CFUs 
were performed five days post initial viral infection. Mice were monitored daily during the 
course of infection and euthanized when reaching a weigh loss of 25%. 
2.19 In vivo indomethacin treatments 
 
Intraperitoneal treatments with indomethacin (1.2mg/kg) were given to 
anesthetized mice at the time of P. aeruginosa infection. Lung and BALF were 
harvested 24hours post-infection. 
2.20 In vivo IFN-γ neutralization 
 
Influenza infected mice were treated with 200µg of IFN-γ neutralizing antibody 
(XMG1.2; BioXcell; West Lebanon, NH) or its isotype control (HRPN; BioXcell; West 
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Lebanon,NH) intraperitoneally on day 5 post-influenza infection prior to a secondary 
bacterial infection with MRSA (7x107 CFUs). Successful neutralization was confirmed by 
measuring IFN-γ levels in BALF by ELISA. 
2.21 In vivo TLR9 inhibition 
 
TLR9 inhibition was achieved by treating mice with three doses (50µg/each) of 
TLR9 inhibitor (ODN 2088; InvivoGen; San Diego, CA) and/or its control (ODN 2088 
Control; InvivoGen; San Diego, CA) on day 0, 2, and 5 post-influenza infection. 
2.22 FITC-labeling bacteria 
 
Bacteria were grown at a density of 6x106 CFUs/µl and heat inactivated by 
incubating for 15min in 70oC using a heat block. Heat killed bacteria were centrifuged at 
13,000 rpm for 5 mins. Supernatant was removed and 1ml of 0.1M NaHCO3 was added 
to the pellet followed by 20μl of a 10mg/ml FITC (Sigma-Aldrich) DMSO solution. 
Bacteria stock was then incubated protected from light, rocking for an hour at room 
temperature. Bacterial stock was then washed 3 times with PBS by centrifuging at 
13,000 rpm for 5mins. Bacteria-FITC stock was then stored on -80oC. 
2.23 Bacterial phagocytosis assay 
 
Cells were plated at 200,000 cells/well in 100μl on a half-area black 96-well plate 
(black with clear bottom) (Corning 3882). Cells were then incubated for an hour, media 
was removed, and cells were washed with cold PBS prior to adding 100µl of complete 
medium containing FITC-labeled heat inactivated bacteria (10ul of FITC-bacteria stock 
per 100ul of media). Cells were then incubated at 37oC for 2 hours before adding 50μl 
of trypan blue (Sigma-Aldrich) to quench extracellular fluorescence. Intracellular 
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fluorescence was measured at (485ex/535em) with a bottom read using the Spectra 
Max M3 (Molecular Devices, LLC). Media was discarded and cells were washed with 
PBS. We then added 110μl of PBS with 2% TritonX-100 per well and incubated plates 
on ice. We next used this media to measure intracellular lactate dehydrogenase (LDH) 
with the Cytotoxicity Detection Kit assay (Roche). Briefly, to do this, we mixed equal 
parts of LDH reagents and sample in a 96 well flat-bottom plate, incubated for 15 
minutes at 37oC and measured absorbance at 490nm using a plate reader. 
2.24 Tetrazolium Dye Reduction Assay (MTT assay) of Bacterial Killing 
 
AMs, lung macrophages, or BMDMs were placed into duplicate 96-well plates: 
one experimental plate and one control plate. Cells from both plates were infected with 
IgG-opsonized P. aeruginosa, S. pnuemoniae, or S. aureus (multiplicity of infection 
50:1) for 30 min at 37°C. The cells on the experimental plate were washed and then 
incubated with or without treatments at 37°C for 120 min, whereas the cells on the 
control plate were washed and then lysed with 0.5% Saponin (Sigma-Aldrich) in growth 
medium (Tryptic soy broth, P. aeruginosa; Todd Hewitt broth, S. pnuemoniae; Nutrient 
broth, S. aureus) and placed at 4°C. After 2 hours, the cells from the experimental plate 
were lysed with 0.5% Saponin in growth medium. Both plates were then incubated in a 
shaker at 37°C for 4h for P. aeruginosa and S. aureus of at 37oC with 5%CO2 with no 
shaking for S. pneumoniae. Thiazolyl blue Tetrazolium Bromide (MTT) assay was 
performed as recommended by the company. Briefly, a total of 5 mg/ml MTT (Sigma) 
was added to each plate and incubated for 30 min. Solubilization solution was added to 
dissolve formazan salts, and the absorbance was read at 595 nm (A595). Results were 
expressed as percentage of survival of ingested bacteria normalized to the percentage 
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of control, where the A595 experiment values were divided by the average of the A595 
control values. Survival of ingested bacteria = (A595 experimental plate/A595 control 
plate) × 100%. 
2.25 H2O2 detection assay 
 
Cellular H2O2 secretion was determined from LPS-recruited neutrophils via 
Amplex Red agent. 
2.26 Sytox green fluorescence assay 
 
Neutrophil extracellular traps (NETs) release was quantified using a cell- 
impermeable nucleic acid dye, Sytox Green, post bacterial challenge or PMA treatment. 
Briefly, 1x105 neutrophils, from human or mice, were seeded in a black with clear 
bottom, non-treated, flat bottom 96-well plate (Costar 3631, Corning, NY). Sytox Green 
Nucleic Acid Stain (s7020; Invitrogen, Carlsbad, CA) was added at the time of 
treatments at a final concentration of 0.2 μM. Cells were incubated for 5 hours before 
adding 100 μL of 4% PFA to every well followed by storing at 4°C overnight protected 
from light. Next day fluorescence was measured at 485nm/525nm. 
2.27 Immunofluorescence 
 
To visualize NETs, 2x105 neutrophils were seeded in poly-lysine-coated cover 
slips, and treatments were added directly for 5-7 hours (murine) or 3 hours (human), 
before cells were fixed and stained with anti-neutrophil elastase and Hoescht. For 
autophagy experiments, alveolar macrophages were harvested by BAL and 1.5-2x105 
cells were seeded in poly-lysine-coated cover slips cells were cell were nutrient starved 
and/or treated with PGE2 (100nM) for 4 hours before fixation. Cells were permeabilized 
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with TBS- with 0.2% of Triton-X, and cover slips were blocked with 5% BSA. Primary 
antibody was incubated for 4 hours, and secondary antibody was incubated for 2 hours. 
After antibody incubations, prolong Gold anti fade reagent with DAPI (Invitrogen) was 
added to the cells. Immunofluorescence images were taken with the use of an Olympus 
500 confocal microscope (Olympus Corporation, Center Valley, PA). 
2.28 Western blotting and protein measurements 
 
Cell lysates were obtained using RIPA buffer (Thermo Fisher; Waltham, MA) with 
protease inhibitor (Calbiochem; San Diego, CA) and samples were centrifuged at 
15,000rpm to remove debris. Pierce BCA assay kit (Thermo Fisher; Waltham, MA) was 
used for quantification of total amount of protein in cell lysate. Around 20-50μg of total 
protein from samples were mixed with laemmli buffer (Bioland Scientific LLC; 
Paramount, CA ) containing β-mercaptoethanol and heated at 95oC for 10min. Protein 
samples were separated in a polyacrylamide gel using a mini gel tank (Invitrogen, 
Carlsbad, CA), following by transferring protein to a polyvinylidene fluoride (PVDF) 
membrane that was blocked with 5% non-fat milk. Incubation with primary antibody was 
done overnight at 4oC. Multiple washes of TBS with 0.5% of Tween 20 were performed 
before incubation with secondary antibody for 1-2 hours at room temperature. Images 
were taken with the Amersham Imager 600 (GE Healthcare) and in some cases 
densitometry was obtained with Image Studio Lite version 5.2. 
2.29 ELISA 
 
Cytokine measurements were performed with the use of R&D duo set ELISA kits 
for murine IFN-γ, TNF-α, IL-1β, IL-6, IL-10, and IL-17. Murine albumin measurements 
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were performed with the use of the Bethyl laboratory (Montgomery, TX) albumin ELISA 
kit. 
2.30 Histology 
 
Hematoxylin and Eosin stain was performed after perfusion of the lung with PBS 
and tissue fixation with 10% formalin. Tissues were left in 10% formalin overnight before 
replacing with 70% ethanol. Lung samples were processed and stained by McClinchey 
Histology Services (Stockbridge, MI). 
2.31 Real-time quantitative PCR 
 
mRNA was isolated using TRIzol according to the manufacturer’s instructions. 
 
Relative gene expression measurements were achieved with the use of a Step-one plus 
real-time PCR system from Applied Biosystems (Foster City, CA). Gene-specific 
primers and probes were designed with the Genscript Real-time PCR primer design 
software (Genscript Biotech Corporation, Piscataway, NJ). 
 
 
 
Table 2-1 List of Primers and Probes used in qRT-PCR: 
 
 
Name Sequence (5'-3') Strand Modification 
 
TLR2 
ATGGGCTCGGCGATTTC Forward  
ATGCAACCTCCGGATAGTGACT Reverse  
CGGAGTCAGACGTAGTGAGCGAG Probe 5'Fam - 3'Tamra 
 
TLR3 
GCCCTCCTCTTGAACAACGC Forward  
ACTTCAGCCCAGAGAAAGTGCT Reverse  
ACCAGCTGCTGGCCACCAGCGAG Probe 5'Fam - 3'Tamra 
 
TLR4 
AAGGAGTGCCCCGGTTTC Forward  
CACAATAACCTTCCGGCTCTTG Reverse  
TGCCAACATCATCCAGGAAGGCT Probe 5'Fam - 3'Tamra 
TLR7 TCTGCAGGACCTCTGTCCTTG Forward  
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 TGATTGTCTGTGGTCAGGGCAT Reverse  
TGGCCTGCAAATCCACAGGCTCACCCA Probe 5'Fam - 3'Tamra 
 
TLR9 
GAGTACTTGATGTGGGTGGGAAATT Forward  
GCCACATTCTATACAGGGATTGG Reverse  
CCGTCGCTGCGACCATGCC Probe 5'Fam - 3'Tamra 
 
iNOS 
ACATCAGGTCGGCCATCACT Forward  
CGTACCGGATGAGGCTGTGAAT Reverse  
CCCCACCGGAGTGACGGCA Probe 5'Fam - 3'Tamra 
 
MARCO 
CCTGGACGAGTCGGTCAGAA Forward  
CTTCAGCTCGGCCTCTGTT Reverse  
CCAACGCGTCCGGATCATGGGT Probe 5'Fam - 3'Tamra 
 
SRAI/II 
TGAAGGACTGGGAACACTCACA Forward  
CAGTAAGCCCTCTGTCTCCCTTT Reverse  
TTCATTCAAGGGCCTCCTGGACCC Probe 5'Fam - 3'Tamra 
Influenza 
A virus 
GGACTGCAGCGTAGACGCTT Forward  
CATCCTGTTGTATATGAGGCCCAT Reverse  
CTCAGTTATTCTGCTGGTGCACTTGCCA Probe 5'Fam - 3'Tamra 
 
IL-1β 
GAGCCCATCCTCTGTGACTCA Forward  
GTTGTTCATCTCGGAGCCTGTAG Reverse  
AACCTGCTGGTGTGTGA Probe 5'Fam - 3'Tamra 
Human 
IL-1β 
AAGCTGAGGAAGATGCTGGT Forward  
CGTTATCCCATGTGTCGAAG Reverse  
CCTGCCCACAGACCTTCCAGG Probe 5'Fam - 3'Tamra 
 
COX-1 
CTTCTTAGGGAATCCCATCTG Forward  
CTTCAGTGAGGCTGTGTTGACAAG Reverse  
ACCCAGCACCTTCGGTGGT Probe 5'Fam - 3'Tamra 
 
COX-2 
TGACCCCCAAGGCTCAAAT Forward  
GAACCCAGGTCCTCGCTTATG Reverse  
TTTGCCCAGCACTTCACCCACAGT Probe 5'Fam - 3'Tamra 
 
ATG5 
TCAAGTTCAGTGGAGGCAAC Forward  
TGGAATGTTCTCCTCCTTGG Reverse  
CTTGCAGCAGCCCGGGTTTC Probe 5'Fam - 3'Tamra 
 
β-Actin 
CCGTGAAAAGATGACCCAGATC Forward  
CACAGCCTGGATGGCTACGT Reverse  
TTTGAGACCTTCAACACCCCA Probe 5'Fam - 3'Tamra 
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2.32 Flow cytometry 
 
Lung immune cells were obtained after lung perfusion, and whole lung digestion 
with Collagenase A. Cells were then stimulated with PMA (20nM), ionomycin (1μM) and 
protein transport inhibitor (Golgi stop) for 4-6 hours in treated cell culture dishes. After 
incubation, cells were centrifuged and washed in FA buffer with 2% FCS. Staining with 
antibodies for myeloid or lymphocyte population were performed at 4oC for 30min. Cells 
were the fixed and permeabilized overnight with Fix/perm solution (Foxp3 / 
Transcription Factor Staining Buffer Set, Invitrogen). Next day the cells were stained for 
intracellular markers for 30mins at 4oC. Cells were washed and diluted in PBS before 
analyzing in a Fortessa cell analyzer (BD Biosciences; San Jose, CA). 
2.33 Flow cytometry antibodies 
 
TLR9 (J15A7; BD Biosciences; San Jose, CA), IgG1 (MOPC-21; BD 
Biosciences; San Jose, CA), CD45 (30-F11; BD Biosciences; San Jose, CA), CD11b 
(M1/70; BD Biosciences; San Jose, CA), CD11c (N418; Biolegend; San Diego, CA), 
Siglec F (E50-2440; BD Biosciences; San Jose, CA), MHC II (I-A/I-E) (M5/114.15.2; BD 
Biosciences; San Jose, CA), CD64 (X54-5/7.1; Biolegend; San Diego, CA), F4/80 (BM8 
eBiosciences; SanDiego, CA), LY6G (1A8; BD Biosciences; San Jose, CA), CD3 (17A2, 
BD Biosciences; San Jose, CA), CD90.2 (53-2.1; BD Biosciences; San Jose, CA), CD4 
(GK1.5; Biolegend; San Diego, CA) CD8 (53-6.7; BD Biosciences; San Jose, CA), 
NKP46 (29A1.4; Biolegend; San Diego, CA), CD19 (1D3; BD Biosciences; San Jose, 
CA), Fc Block(CD16/CD32) (2.4G2; BD Biosciences; San Jose, CA). 
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2.34 Statistical analysis 
 
Graphpad Prism version 6 software (Graphpad Prism Software Inc., La Jolla, CA) 
was used to analyze experimental results. When groups of two were compared, 
student’s T-test was used to determine statistical significance. Groups of ≥ 3 were 
compared using one-way analysis of variance with Bonferroni multiple mean 
comparisons. Fisher exact test was used to compare clearance of bacteria and albumin 
levels between Pseudomonas aeruginosa infected mice. In human studies, the following 
steps were used to normalize patient data according to patient-specific outcomes in the 
media treatment group. First the mean across an individual’s media replicates was 
calculated. This individual-specific mean was then used to rescale outcomes from all 
experimental conditions for that individual, via division, giving a mean media outcome in 
each individual of 100. Other experimental conditions are then summarized as 
percentage of control units (above or below 100% with media group as reference). 
Mixed models with a random intercept for individual were used to estimate experimental 
condition means and corresponding 95% confidence intervals used in the figures; 
correlation between outcomes within individual are accounted for via the random 
intercept term. A P value less than 0.05 was considered statistically significant. 
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Chapter 3. 
 
Elevated Prostaglandin E2 Post-Bone Marrow Transplant Mediates Interleukin- 
1β Related-Lung Injury 
3.1 Background 
 
Hematopoietic stem cell transplant (HSCT) utilizes stem cells derived from bone 
marrow, umbilical cord blood, or peripheral blood to treat or cure a variety of 
hematological disorders1. This procedure has become a standard of care with more 
than 18,000 HSCT performed every year in the United States alone1. HSCT requires a 
conditioning regimen (e.g. total body irradiation and/or chemotherapy) to allow the 
patient’s hematopoietic system to be replaced by donor cells. Depending on disease, 
the patient can undergo autologous (self-donation of stem cells) or allogeneic (stem 
cells from a Human Leukocyte Antigen (HLA)-matched donor) transplants. 
Unfortunately, patients that undergo HSCT become immunosuppressed and susceptible 
to infections by opportunistic pathogens2. Around 60% of HSCT patients develop 
pulmonary complications, many of them due to bacterial infections, which correlate with 
high mortality and morbidity1-3. Infections post-HSCT are independent of conditioning 
regimen and type of transplant as both autologous and allogenic patients are highly 
susceptible. Infections can take place in the pre-engraftment phase (before 30 days 
post-transplant) as well as after immune reconstitution (after 30 days post-transplant)3. 
Although infections can be caused by viral, bacterial, or fungal organisms, bacterial 
infections are increasingly problematic due to the rise in drug-resistant bacteria. 
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Bacterial infections post-HSCT can occur in 51.3% of HSCT patients2. These 
infections, including infections by the Gram negative bacterial pathogen, Pseudomonas 
aeruginosa, cause life-threatening complications2. 
P. aeruginosa is an opportunistic pathogen that normally infects immunocompromised 
individuals such as HSCT patients2, 4-7. It is a leading nosocomial pathogen, and it is 
the most frequently isolated Gram negative bacteria in the intensive care unit 8. This 
pathogen causes urinary tract infection, hospital-acquired pneumonia, and bacteremia 
in burn patients9. It is also the predominant cause of morbidity and mortality in Cystic 
Fibrosis patients. There has been a significant increase in research effort studying P. 
aeruginosa due to the difficulty of treating infected patients, as 26% of its isolates are 
resistant to antibiotics and disinfectants 8. Understanding how to modulate P. 
aeruginosa infections in an antibiotic-independent method is likely to have positive 
impacts on the outcome of infected patients. Although many antimicrobial pathways 
have been linked to P. aeruginosa clearance, induction of inflammasome activation and 
Interleukin 1β (IL-1β) secretion play pathogenic roles during P. aeruginosa infection5. 
The inflammasome is a multi-protein complex expressed mainly in immune cells and 
activated by pathogenic stimuli. Its activation leads to secretion of two potent 
inflammatory cytokines, IL-1β and IL-18. Their secretion pathways are complex and 
partially unknown, but have been well established to require two signals. Signal one 
leads to up-regulation of immature pro-cytokines and is mediated by Toll-like receptor 
(TLR) stimulation by pathogen-associated molecular patterns (PAMPs). Gram negative 
bacteria like P. aeruginosa can trigger signal one by stimulation of TLR4 and TLR5 via 
lipopolysaccharide (LPS) and flagella, respectively10-12. Signal two can be triggered by a 
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wide array of pathogenic stimuli that culminate in aggregation of inflammasome 
components (e.g. caspase-1 or NOD-like receptor proteins) and result in secretion of 
mature IL-1β and IL-18. P. aeruginosa can induce signal two via recognition of type III 
secretion proteins. Although a protective mechanism against many pathogens, 
overproduction of IL-1β has been associated with auto-inflammatory syndromes such as 
gout and periodic fever syndromes, such as Familial Mediterranean Fever and 
cryopyrin-associated periodic fever syndromes (CAPS)13. Therapies targeting IL-1β 
signaling have shown better outcomes in CAPS patients14. Moreover, asbestos and 
silica inhalation can cause IL-1β-dependent pulmonary fibrosis mediated by alveolar 
macrophage (AMs)15. In the lung, P. aeruginosa can induce IL-1β secretion by AMs5. 
Interestingly, depleting AMs prior to P. aeruginosa infection leads to significantly lower 
levels of IL-1β in the lung, improving survival5. Apart from IL-1β secretion, P. aeruginosa 
infection has also been shown to be regulated by prostaglandin E2 (PGE2)6, 7, 16. 
PGE2 is a lipid mediator derived from arachidonic acid by the enzymatic activity of 
cyclooxygenase (COX) and PGE synthases that signals through 4 different G-protein- 
coupled plasma membrane receptors (GPCRs) of the E-prostanoid (EP) family termed 
EP1, EP2, EP3, and EP4. Each receptor activates different intracellular pathways. 
Stimulation of EP1 receptor increases intracellular calcium and activation of protein 
kinase C which stimulates the transcription factors, NFAT and NFκB 17. EP2 and EP4 
receptors are stimulators of adenylyl cyclase (AC) and phosphoinositide 3-kinase (PI3K) 
, respectively. AC mediates conversion of ATP to cyclic adenosine monophosphate 
(cAMP) leading to activation of protein kinase A (PKA) and the transcription factor 
CREB. The EP3 receptor is a regulator of the EP2-EP4 signaling pathway as its 
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activation leads to inhibition of AC. P. aeruginosa infection increases levels of inducible 
COX-2 leading to high levels of PGE2 and inhibition of COX2, with subsequent 
diminished production of PGE2, can lead to a better outcome in P. aeruginosa-infected 
mice 7. Interestingly, HSCT patients possess higher levels of PGE2 in blood and 
bronchoalveolar lavage (BAL) when compared to healthy non-transplanted individuals18, 
19. 
 
PGE2 is dysregulated in HSCT patients18 and suppression of PGE2 confers protection 
against P. aeruginosa infection in murine HSCT models 6 . However, other roles of 
PGE2 in the context of HSCT and pulmonary P. aeruginosa infection remain elusive. To 
study bacterial lung infections post-HSCT, we use a mouse model of syngeneic bone 
marrow transplant (BMT). Total body irradiation is used as a conditioning regimen6, 20-22. 
Experiments are performed in the post-engraftment period, 5 weeks post-BMT when 
lung leukocytes are composed of 82% donor cells and splenic leukocytes are 95% 
donor cells20. We previously reported BMT mice are deficient in phagocytosis and killing 
of P. aeruginosa6, 23, correlating with observations in humans2. In the present study, we 
compare the cytokine profile and lung tissue injury of control and BMT mice post P. 
aeruginosa infection. We also tested the direct relationship of PGE2 with P. aeruginosa- 
induced IL-1β and examined the effect that PGE2 stimulation had on autophagy, a main 
mechanism of P. aeruginosa clearance by AMs that has also been linked to 
inflammasome regulation24, 25. 
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3.2 Results 
 
Bone Marrow Transplant (BMT) mice are deficient in clearing P. aeruginosa 
infection and experience exacerbated lung tissue injury. BMT mice are deficient in 
clearing a P. aeruginosa PAO-1 infection compared to healthy control mice 24 hours 
post-infection (Fig.3-1A) confirming published data6. Deficiency in clearing bacteria is 
not due to low numbers of immune cells in the alveolar compartment as there are no 
differences in cell numbers or percentages of monocyte/macrophages and lymphocytes 
in the bronchoalveolar lavage (Fig.3-2A, B) between groups. We also noted higher 
levels of albumin in the bronchoalveolar lavage fluid (BALF) of BMT mice compared to 
control mice (Fig. 3-1b) suggesting more severe pulmonary injury (Fig.3-1c). Acute lung 
injury (ALI) is a leading cause of death in the intensive care unit, characterized by 
accumulation of leukocytes, protein leakage, and epithelial injury. ALI has been linked to 
high levels of IL-1β in the lung 26. Thus, we measured levels of several pro-inflammatory 
cytokines. We found higher levels of IL-1β, but not other pro-inflammatory cytokines (IL- 
6, IL-12, TNF-α; data not shown) in BALF from infected BMT mice compared to control 
mice (Fig.3-3A). We tested levels of PGE2 in BALF and detected higher levels of PGE2 
in BMT mice infected with PA01 compared to infected control mice. Moreover, we 
noticed mice expressing higher levels of PGE2 have direct and significant correlations 
between levels of IL-1β and tissue injury, but not with other cytokines such as TNF-α 
(Fig.3-3C-F). Previous research has suggested a role for PGE2 in IL-1β induction27, 28. 
Thus, exacerbated levels of IL-1β post-P. aeruginosa infection might mediate lung 
tissue injury and be dependent on PGE2. Additionally, P. aeruginosa-mediated IL-1β 
release has 
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Figure 3-1: BMT Mice are Deficient in Clearing P. aeruginosa Infection and Experience Exacerbated Lung Tissue 
Injury. (a) Colony Forming Units (CFUs) were counted 24 hours after infecting non-transplanted control and BMT mice 
(C57BL/6J→C57BL/6J) with 5x105 CFUs of Pseudomonas aeruginosa (PA01). (n=5 control; n=5 BMT). (b) Albumin 
measurements from bronchoalveolar lavage fluid (BALF) from PA01 infected control and BMT mice. (n=7 control; n=6 
BMT) (c) Hematoxylin and Eosin stain (H&E) of lungs from saline or PA01 infected control and BMT mice; images taken at 
40x magnification (representative of n=3 control; n=3 BMT). Statistics are student T test between comparative groups. 
*P˂0.05. Data is representative of at least two independent experiments. 
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been shown to be dependent on alveolar macrophages (AMs) 5, 26. Thus, we directed 
our attention to AMs in BMT mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2: Leukocytes in BALF Post-BMT. (a) Absolute number of leukocytes in BALF, quantified with a 
hemocytometer, (n=3). (b) Percentage of leukocytes from BALF, taken via differential staining, (n=4). Statistics done 
by student T test. Not significant (NS). 
 
Pro-inflammatory AMs in BMT mice account for higher levels of IL-1β in response 
to P.aeruginosa infection. To determine sources of IL-1β and PGE2 in the lung, we 
compared mRNA levels from AMs obtained by BALF to lung interstitium. Transcripts for 
the rate limiting enzymes in PGE2 synthesis, cyclooxygenase (COX) 1 and 2, were 
higher in AMs from BMT mice compared to control (Fig.3-4A). This was unique to AMs, 
but not interstitial samples. In addition, AMs from BMT mice have higher levels of IL-1β 
transcripts compared to control cells (Fig.3-4A). Consistent with our past studies, 
overnight culture of AMs from BMT mice secreted higher levels of PGE2 compared to 
cells from control mice (Fig.3-4B). To assess whether PGE2 can have an effect on IL-1β 
secretion, we pre-treated AMs with or without PGE2 prior to PA01 infection, in vitro. We 
detected higher levels of IL-1β in supernatants of AMs pretreated with PGE2 and 
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infected with PAO1 compared to AMs infected with PA01 alone (Fig.3-4C). Moreover, to 
determine whether higher bacterial burden in BMT mice was responsible for higher 
levels of IL-1β, we induced acute lung injury with lipopolysaccharide instillation in control 
and BMT mice. We detected higher IL-1β, but not IL-6 or TNF-α in BALF from BMT 
mice compared to control mice post-LPS instillation (Fig.3-4 D-F). 
PGE2 induces higher levels of IL-1β upon pathogenic stimuli. To assess whether 
PGE2 could induce IL-1β in macrophages other than AMs, we prepared bone marrow 
derived macrophages (BMDMs) from healthy mice and pretreated them with PGE2 prior 
to PA01 infection, in vitro. Similar to AMs, we detected higher IL-1β, but not IL-10, in 
supernatants of PGE2- stimulated cells compared to non-treated cells post-PA01 (Fig.3- 
5A-B). In addition, to detect whether PGE2-mediated higher levels of IL-1β with different 
stimuli; we pretreated BMDMs with and without PGE2 and stimulated cells with LPS, 
and/or heat-killed PA01. In all cases, PGE2 pretreatment increased levels of IL-1β 
compared to non-treated cells (Fig.3-5C). A canonical method to achieve IL-1β 
secretion is to activate the NLRP3 inflammasome by stimulation of the pannexin-1 
channel and the purinergic P2X7 by LPS priming and adenosine triphosphate (ATP) 
treatment25, 28-30. We also detected higher IL-1β in BMDMs pretreated with PGE2 and 
treated with LPS and ATP when compared to treatment with LPS and ATP alone (Fig.3- 
5D). Furthermore, we noted higher levels of IL-1β in BMDMs pre-treated with PGE2 and 
infected with methicillin-resistant Staphylococcus aureus (MRSA) or Streptococcus 
pneumoniae compared to infected BMDMs not treated with PGE2(Fig.6B). MRSA and 
S.pneumoniae are also main pathogens that infect immunosuppressed individuals6, 19, 
31, 32. 
60 
 
 
 
 
Figure 3-3: P. aeruginosa Infection Induces Higher Levels of IL-1β and PGE2 post-BMT Correlating with 
Increased Lung Injury. (a) IL-1β and (b) PGE2 measurements from the BALF of control and BMT mice 24 hours 
after infection with PA01; measurements done by ELISA. (n=7 control; n=6 BMT); (c) Correlation between albumin 
and IL-1β in BALF 24h post-PAO1; (d) Correlation between albumin and PGE2 in BALF 24h post-PAO1; (e) 
Correlation between PGE2 and IL-1β in BALF 24h post-PAO1 ; (f) Correlation between PGE2 and TNF-α in BALF 
24h post-PAO1. In all correlations, closed symbols represent control mice whereas open circles are BMT mice. R= 
Pearson correlation coefficient; *P˂0.05. 
PGE2-mediated increase in IL-1β is dependent on activation of transcription factor 
CREB via increased levels of cAMP dependent on EP2 and EP4 signaling. We next 
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probed PGE2 signaling pathways. We stimulated PGE2 receptors using pharmacologic 
agonists for the EP2, EP3, and EP4 receptors17. A selective EP1 agonist is not 
available. We found pre-stimulating BMDMs with EP2 and EP4 agonists lead to higher 
levels of IL-1β post-P.aeruginosa infection (Fig.3-7A). EP3 stimulation did not lead to 
higher IL-1β (data not shown). EP2 and EP4 receptors activate adenylate cyclase (AC) 
and increase cyclic adenosine monophosphate (cAMP) from cytosolic ATP. We 
pretreated BMDMs with the AC stimulator forskolin prior to PA01 infection and observed 
higher levels of IL-1β in forskolin-pretreated BMDMs (Fig.3-7B). Moreover, as increased 
levels of cAMP lead to the activation of protein kinase A (PKA) and Epac (exchange 
protein directly activated by cAMP), we used agonists for the activation of these two 
proteins 33. We found higher levels of IL-1β in supernatant of BMDMs pre-stimulated 
with PKA and Epac agonists prior to PA01 infection (Fig.3-7C). PKA and Epac 
activation lead to activation of the transcription factor CREB, thus, we used a CREB 
inhibitor during PGE2 stimulation prior to PA01 infection. We decreased the levels of 
PGE2 mediated-IL-1β using the CREB inhibitor (Fig.3-7D). Thus, PGE2 increases IL-1β 
by activation of the transcription factor CREB via stimulation of EP2 and/or EP4 
receptors. 
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Figure 3-4: Alveolar Macrophages in BMT Mice Account for Higher IL-1β Release post-P.aeruginosa in 
Response to PGE2. (a) RTqPCR measurement of relative gene expression of Cox-1, Cox-2, and IL-1β from AMs 
and whole lung cells from uninfected control and BMT mice normalized to GAPDH (n=3 control; n=3 BMT/group). (b) 
PGE2 measurements by ELISA from overnight culture of untreated AMs from control and BMT mice (n=4 Control; n= 
4 BMT). (c) IL-1β measurements by ELISA from AMs infected or not in vitro with PA01 (MOI:10), treated or not with 
100nM of PGE2 (n=3). (d) IL-1β, (e) TNF-α and (f) IL-6 measurements by ELISA from BALF of LPS (50ug)-treated 
control and BMT mice (n=10 control, n=10 BMT). Statistics are student T test between comparative groups. *P˂0.05 
,**P˂0.01, ***P˂0.001, ****P˂0.0001. Data is representative of at least two independent experiments. 
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PGE2-dependent IL-1β release post-P. aeruginosa infection can be mediated by 
canonical or non-cannonical inflammasomes and is independent of autophagy 
inhibition. Mycobacterium tuberculosis and Candida albicans have been shown to 
induce IL-1β by a non-canonical inflammasome pathway dependent on caspase-8 in 
macrophages34, 35. Although a role of caspase-8-mediated IL-1β processing post- 
P.aeruginosa infection hasn’t been proposed, research has shown that P.aeruginosa- 
infected caspase-1 deficient mice can secrete normal levels of IL-1β compared to 
control mice36. Thus, other proteases might play a role in processing pro-IL-1β post- 
P.aeruginosa infection. We stimulated macrophages with or without caspase-1 and 
caspase-8 inhibitors. Interestingly, in both cases, IL-1β secretion was inhibited with or 
without the effects of PGE2 (Fig.3-8A-B). Stimulating macrophages with LPS and ATP in 
the presence or absence of caspase-1 and/or caspase-8 inhibitors confirmed the 
specificity of these inhibitors (Fig.3-9). AMs can clear P.aeruginosa infection by 
autophagy and IL-1β release can be negatively regulated by autophagy24, 25. 
Autophagy can be induced by serum starvation; thus, we tested effects of PGE2 on 
autophagy-enhanced clearance of P. aeruginosa carried out under conditions of serum 
deprivation. Our results indicate PGE2 can inhibit autophagy-dependent clearance in 
AMs (Fig.3-10). To detect whether there is a direct effect of PGE2 on autophagy, we 
treated BMDMs with different concentrations of PGE2 and detected levels of the 
autophagy-related proteins, LC3 and P62. We detected downregulation of LC3 and 
accumulation of P62 when we treated AMs with PGE2. These changes are characteristic 
of autophagy inhibition (Fig.3-10B). In addition, we induced autophagy by serum 
starvation with or without PGE2 stimulation and determined that PGE2 inhibits levels of 
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the autophagy-related protein, ATG5, by western blot and RTqPCR (Fig.3-10C). 
Although we found PGE2 inhibits autophagy, autophagy-deficient BMDMs were still able 
to upregulate IL-1β release when PGE2 was present, suggesting PGE2 inhibition of 
autophagy is not required for processing and upregulation of IL-1β (Fig.3-10D). 
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Figure 3-5: PGE2 Increases IL-1β BMDMs Upon Pathogenic Stimulation. (a-b) IL-1β and IL-10 measurements from 
supernatants of PA01 infected (MOI:10) BMDMs treated or not with 100nM PGE2. (c) IL-1β measurements from supernatant 
of BMDMs treated with lipopolysaccharide (LPS) derived from P. aeruginosa (500ng/ml), heat killed PA01 (MOI:10), and (c) 
ATP (1mM) with LPS with or without 100nM of PGE2. Supernatant taken 2 hours post-stimulation. One-way ANOVA with 
Bonferroni’s post-test. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. Data is representative of three independent 
experiments. 
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PGE2 elevated the levels of IL-1β transcripts by EP2 and EP4 stimulation in 
human and mouse cells. Considering that neither autophagy inhibition nor 
inflammasome activation explain why PGE2 boosted IL-1β release; we next studied the 
transcriptional effects of PGE2 on IL-1β. We treated BMDMs with PGE2 in a dose and 
time dependent manner and detected significant increases in IL-1β transcripts as soon 
as 2 hours post-PGE2 stimulation (Fig.3-11A-B). Furthermore, we confirmed elevated 
levels of IL-1β transcripts by PGE2 stimulation are dependent on increasing levels of 
cAMP by stimulation of EP2 and/or EP4 receptors but not by EP3 stimulation (Fig.3- 
11C). Moreover, we confirmed our findings in human peripheral monocytes and human 
AMs (Fig.3-12). 
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Figure 3-6: PGE2 Enhances IL-1β Release Under Different Pathogenic Stimuli. (a) IL-1β measurements of supernatant 
from BMDMs treated or not with PGE2 (100nM) and infected or not with PA01 (MOI:10) for 30 minutes after which supernatant 
was replaced with complete media containing 1% gentamycin. (b) IL-1β measurements of supernatant after MRSA (MOI:10) or 
S. pneumoniae (MOI:10) infection with or without PGE2 (100nM). Samples were taken two hours after infection. Statistics used 
one-way ANOVA with Bonferroni’s post-test. *P˂0.05 ,**P˂0.01, ***P˂0.001. Data is representative of three independent 
experiments 
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Figure 3-7: PGE2 Mediated Increase in IL-1β is Dependent on Activation of Transcription Factor 
CREB by Increasing Levels of cAMP Dependent on EP2 and EP4 Signaling. IL-1β measurements 
from supernatant of BMDMs treated or not with PAO1 (MOI:10) with or without (a) EP2 agonist (1μM, 
Butaprost), EP4 agonist (500nM, ONO-AE1-329) (b) forskolin (25μM), PGE2 (100nM), (c) PKA agonist 
(50μM, 6-BNZ-cAMP), Epac agonist (50μM, 8-pcpt-2’-OM-cAMP). (d) IL-1β protein measurement from 
supernatants of BMDMs treated or not with 100nM of PGE2, CREB inhibitor (100μM, Naphthol AS-E 
phosphate) and infected or not with PA01 (MOI:10). In all cases, supernatant taken 2 hours after 
infection. One-way ANOVA with Bonferroni’s post-test. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. 
Data is representative of two independent experiments. 
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Decreasing levels of PGE2 reduces P. aeruginosa-mediated lung tissue injury. 
Increased levels of IL-1β post-P.aeruginosa infection aggravate lung tissue injury4, 5. 
Therapeutic strategies using caspase-1 inhibitors reduced severity of IL-1β pulmonary 
injury 26. However, other research has shown that inhibiting IL-1β signaling has no 
impact on bacterial burden or immune cell recruitment, with minimal effects on lung 
injury36. As we have shown that PGE2 elevation in BMT mice aggravates lung injury, we 
tested the effect that PGE2 inhibition had on lung injury outcomes. We instilled P. 
aeruginosa to control and BMT mice with or without administration of the COX inhibitor, 
indomethacin. We noted reduced IL-1β in the BALF as well as lower levels of protein 
leakage, suggesting inhibition of PGE2 can decrease levels of ALI post-P.aeruginosa 
infection (Fig.3-13). 
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Figure 3-8: PAO1 can use cannonical or non-cannonical inflammasomes to make IL-1β. IL-1β measurements 
from supernatant of BMDMs treated or not with (a) Caspase 8 inhibitor (10nM) or Caspase 1 inhibitor (10nM) with or 
without PGE2 (100nM). Supernatant taken 2 hours after infection. One-way ANOVA with Bonferroni’s post-test. 
*P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. Data is representative of two independent experiments 
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3.3 Discussion 
 
In February 2017, the World Health Organization (WHO) published a report 
containing a list of 12 bacterial pathogens for which new therapeutic strategies are 
urgently needed. Pseudomonas aeruginosa was considered to be of critical importance. 
P. aeruginosa is an opportunistic pathogen which causes minimal pathogenicity in 
healthy individuals, but major mortality and morbidity in HSCT patients 2, 6, 19, 31, 37, 38. 
Susceptibility to this pathogen has been reported to occur even after immune 
reconstitution following HSCT2, 6, 31. HSCT patients have high levels of PGE2 in the 
blood and BALF when compared to healthy individuals18-20. We have previously 
reported that elevated PGE2 is causally related to the impaired ability of AMs from BMT 
mice to phagocytize and kill bacteria 20, 23, 39. The purpose of the current study was to 
determine whether PGE2 production post-BMT was responsible for enhanced lung injury 
post-infection as well, and if so, by what mechanism. We now know that 
inflammasome-dependent IL-1β secretion is induced by P. aeruginosa, and better 
health outcomes have been reported by inhibiting IL-1β signaling4, 5, 12, 26, 36. In addition, 
recent articles have linked PGE2 signaling with IL-1β regulation27, 28, 40. However, reports 
have shown contradictory effects of PGE2 on IL-1β release27, 28. Thus, in this study we 
focused on the PGE2-mediated effects on IL-1β response to P. aeruginosa infection by 
AMs from BMT mice in our quest to determine new therapeutic strategies. 
A dose of 2 x 106 CFU P. aeruginosa instilled into un-transplanted mice causes a 
moderate infection 41. Yet, BMT mice have difficulty clearing this bacterial dose and 
100% of them die within 48 hours23. Interestingly, the susceptibility to P. aeruginosa in 
BMT mice is seen even after immune reconstitution6, 23, 42. Here, we show evidence that 
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BMT mice have severe vascular and epithelial leakage indicating a more severe ALI 
post-P.aeruginosa infection. ALI can be caused by exacerbated levels of pro- 
inflammatory cytokines. Thus, we searched for upregulated levels of different pro- 
inflammatory cytokines (IL-12, IL-6, TNF-α, and IL-1β) and found that only IL-1β was 
significantly higher in BMT mice when compared to un-transplanted mice post-infection. 
In addition, we noticed a direct correlation between IL-1β, PGE2, and albumin levels in 
the BALF, but not a correlation with other pro-inflammatory cytokines such as TNF-α. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9: PGE2 Limits Autophagosome Formation in Response to Serum Starvation. BMDMs were serum- 
starved for 1 h in the presence or absence of 100nM PGE2. Cells were fixed and stained with FITC-labeled LC3 or 
DAPI to visualize autophagosomes and nuclei and immunofluorescence images were captured singly or were 
merged. Panels shown are representative of 2 different experiments. 
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AMs from BMT mice have higher levels of IL-1β transcripts compared to control mice, 
correlating with higher levels of cyclooxygenase 1 and 2 transcripts. Furthermore, 
stimulating AMs with PGE2 prior to infection with P. aeruginosa also leads to higher 
levels of IL-1β compared to untreated AMs. These findings show that higher levels of 
PGE2 in AMs from BMT mice might influence the higher levels of IL-1β post- 
P.aeruginosa. 
As higher amounts of bacterial burden in BMT mice might influence the levels of IL-1β, 
we adopted a bacterial-free model of ALI dependent on lipopolysaccharide instillation 43. 
We were able to get exacerbated levels of IL-1β, but not IL-6 and TNF-α, in BMT mice 
compared to un-transplanted mice. In addition, in an in-vitro model where we controlled 
the stimulants, we detected that PGE2 could increase secretion of IL-1β in bone marrow 
derived macrophages by a wide array of pathogenic stimuli such as LPS, live and heat 
killed P. aeruginosa, MRSA infection, and Streptococcus pneumoniae infection. All 
stimuli induce increased IL-1β after previous exposure to PGE2 in macrophages. Thus, 
PGE2 signaling acts as signal 1 for IL-1β secretion. Interestingly, dual stimulation of 
macrophages with PGE2 and another signal-1 stimulant, LPS, can lead to increased IL- 
1β secretion. This phenomenon is likely explained by the moderate activation of 
caspase-1 (signal 2) in macrophages by LPS stimulation as previously noted 44 . 
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Figure 3-10. Inhibition of Autophagy Impacts Bacterial Killing but Not IL-1β Release. (a) AMs were cultured 
in complete media or were nutrient starved (EBSS or HBSS) in the presence or absence of PGE2 (100nM) for 2 
hours. (b) AMs were collected from control mice and stimulated for 1 hour in the presence of serum-free media 
with or without PGE2 (50-500 nM) for 1h. LC3 and p62 was analyzed by Western blot (WB). (c) AMs were cultured 
in complete media or were serum-starved for 1 h with or without 100nM PGE2 before RNA was prepared and 
analyzed for expression of ATG5 relative to β-actin by qRT-PCR; (bottom) ATG5 was analyzed by WB.(d) 
BMDMs from LC3-/- mice were stimulated with 100nM PGE2, PAO1 (MOI:10) or the combination for 2 hours before 
supernatants were collected and measured for IL-1β by ELISA (n=4); Statistics were measured by one-way 
ANOVA with Bonferroni post-hoc test. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. 
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Figure 3-11: PGE2 Elevates the Levels of IL-1β Transcripts by EP2 and EP4 Stimulation. (a) BMDMs were treated or 
not with 100nM PGE2 for 1, 2, 4, and 8 hours before RNA was prepared and analyzed for expression of the IL-1β gene. (b) 
BMDMs were treated or not with 10nM, 100nM, and 500nM of PGE2 during 4 hours before RNA was prepared and 
analyzed for expression of IL-1β. (c) BMDMs were treated with EP2 agonist (1μM, Butaprost), EP3 agonist (10nM, 
Sulprostone), EP4 agonist (500nM, ONO-AE1-329), and forskolin (25μM) before RNA was prepared and analyzed. All 
RNA data was normalized to expression levels of GAPDH. Data are representative of two independent experiments and 
statistics were measured by one-way ANOVA with Bonferroni post-hoc test. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001 
 
 
Recent reports have shown an opposite effect of PGE2 regulation on IL-1β27 than our 
results. We compared their PGE2 stimulation method, based on 5 minutes of stimulation 
by PGE2, side by side with our stimulation method, based on 4 hours pre-stimulation 
with PGE2. As expected, we were able to obtain exacerbated levels of IL-1β post-4 
hours of PGE2 stimulation whereas 5 minutes of stimulation had no effect on IL-1β 
regulation (Fig.3-14). Thus, these comparative results suggest that the kinetics of PGE2 
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exposure is important. However, in the setting of HCST, it is important to remember that 
PGE2 levels are chronically elevated18, 19, and thus, in this setting PGE2 is promoting IL- 
1β. 
PGE2 signaling is mediated by 4 members of the G-coupled protein receptor family 
termed EP1-EP417. We determined that stimulating the EP2 and EP4 receptor in 
macrophages prior to P. aeruginosa infection leads to higher levels of IL-1β when 
compared to non-stimulated macrophages. Furthermore, as EP2/EP4 receptors share 
the ability to activate PKA and Epac, we activated PKA or Epac with the use of 
intracellular agonists prior to P. aeruginosa infection and detected higher levels of IL-1β 
when compared to non-stimulated macrophages. We were able to abolish IL-1β 
secretion in P. aeruginosa-infected mice by stimulating macrophages with an inhibitor 
for the CREB transcription factor. These data indicate that the PGE2-mediated increase 
in IL-1β is due to CREB transcription factor activation by EP2/EP4-mediated stimulation 
of PKA and/or Epac. Although we present evidence that CREB is mediating PGE2- 
dependent elevation of IL-1β, we do not discard the possibility that other transcription 
factors such as NF-κB 28 may also play a role. Furthermore, while both EP2 and EP4 
can mediate the transcriptional effect of PGE2 in macrophages from control mice, in the 
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Figure 3-12: Human AMs and Peripheral Monocytes Upregulate IL-1β under PGE2 stimulation. IL-1β relative 
expression from 100nM PGE2 stimulated (a) Human peripheral monocytes and (b) human AMs normalized to 
GAPDH. (c) IL-1β protein measurements from supernatant of PGE2-treated or not peripheral macrophages during 
or not PA01 infection. Statistics are student T test between comparative groups. *P˂0.05,**P˂0.01, ***P˂0.001, 
****P˂0.0001. 
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setting of BMT, we have previously shown that levels of EP2 are upregulated, while 
EP4 is slightly downregulated on alveolar macrophages and an EP2 antagonist, 
AH6809 was able to mimic effects of indomethacin on alveolar macrophage 
phagocytosis39. 
Researchers have established autophagy as a main mechanism of P. aeruginosa 
clearance 24 as well as IL-1β regulation10, 25. We tested the effects of PGE2 in the 
regulation of autophagy and determined that PGE2 can inhibit autophagy-induced 
clearance of P. aeruginosa. Therefore, these data suggested that PGE2-mediated IL-1β 
increase might be due to autophagy inhibition. However, we detected high levels of IL- 
1β protein in autophagy-deficient macrophages after PGE2 administration and infection. 
Thus, the mechanism of PGE2-mediated increase in IL-1β production cannot be 
attributed to impaired clearance of inflammasome components as a result of defective 
autophagy 25. While we previously demonstrated that PGE2 was associated with 
impaired autophagy in neutrophils19, this is the first description of its ability to limit 
autophagy in macrophages. Thus, PGE2 may be a common negative regulator of 
autophagic flux in other cell types as well. Future work will be needed to understand 
what impact this negative regulation may have on processes such as epithelial repair. 
In macrophages, IL-1β secretion can be mediated by the cysteine proteases, caspase-1 
 
and caspase-835. Thus, we tested the role of these two caspases during P. aeruginosa 
infection. We determined that we could abolish the secretion of IL-1β prior to P. 
aeruginosa infection with the use of inhibitors to caspase-1 or caspase-8. To our 
knowledge, these are the first data to link IL-1β secretion post-P. aeruginosa to 
caspase-8; this pathway has been previously established for Mycobacterium 
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tuberculosis and fungal infection 34.These results suggested that P. aeruginosa infection 
can induce the activation of IL-1β release using either caspase-1 and/or caspase-8. If 
true, this suggests that P. aeruginosa may be able to stimulate non-cannonical 
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Figure 3-13 Decreasing Levels of PGE2 by Indomethacin Treatment Leads to Decreased IL-1β in the Lung after 
P. aeruginosa Infection in BMT mice. (a) IL-1β and (b) albumin measurements from the BALF of control, and BMT 
mice treated or not with Indomethacin (1.2mg/kg) for 24 hours after PA01 infection; measurements done by ELISA. 
(n=14 control; n=14 BMT; n=14 BMT treated with Indomethacin); (C) PA01 CFU measurement in BAL from infected 
mice, 24 hours. (n=10 control; n=10 BMT; n=10 BMT treated with Indomethacin). Statistics were measured by one-way 
ANOVA with Bonferroni post-hoc test. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001; non-significant (ns). 
* * * 
* 
C 
* 
A B 
* 
* * 
IL
 -
 1
 
 
( p
 g
 /
m
 l
 ) 
P
 A
 0
 1
 
B
 a
 c
 t
 e
 r
 ia
 l 
b
 u
 r
 d
 e
 n
 / 
B
 A
 L
 F
 
( 
L
 o
 g
 C
 F
 U
 s
 )
 
A
 lb
 u
 m
 i
n
 

 g
 /
m
 l
 
77 
 
inflammasome activation, possibly via cross-reactivity caused by recognition of P. 
aeruginosa by dectin receptors 45 which are known to be linked to caspase 8 
activation34 . 
Our data suggest that PGE2 can influence a pro-inflammatory environment by 
exacerbating levels of IL-1β, in macrophages. We detected that PGE2 can mediate a 
massive increase in IL-1β transcripts. We detected increased IL-1β transcripts in 
macrophages within an hour post-stimulation with PGE2. Increases in IL-1β transcripts 
were dependent on stimulation of EP2 and EP4 receptors but not by EP3. While we did 
not have access to an EP1-selective agonist, we wouldn’t anticipate this receptor to 
regulate cAMP levels17. Additionally, we were able to detect an increase in IL-1β 
transcripts following activation of cAMP with forskolin. Moreover, PGE2 stimulation 
increased transcription of IL-1β in human alveolar macrophages and human monocyte- 
derived macrophages. Altogether, we conclude that PGE2 can strongly prime 
macrophages for IL-1β, but not other cytokines, and upon pathogenic stimulation will 
lead to exacerbated levels of IL-1β causing IL-1β-mediated injury. Thus, we expected to 
decrease the IL-1β-mediated lung injury post-BMT with the use of COX inhibitors. When 
we tested the effects of PGE2 inhibition in BMT mice, we were able decrease bacterial 
load as previously reported7, but also reduce protein leakage and IL-1β in the lung. 
When our results are taken together, we identified new mechanisms by which P. 
aeruginosa causes life threatening effects in HSCT patients. These findings can help in 
the development of new therapeutic strategies that can improve outcome of HSCT 
patients with pulmonary complications due to P. aeruginosa, and possibly other 
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pathogens. We speculate that COX inhibitors or possibly Anakinra may offer therapeutic 
benefit at limiting lung injury caused by bacterial infection post-HSCT. 
 
 
N S 
 
 
 
2 , 5 0 0 
 
2 , 0 0 0 
 
1 , 5 0 0 
 
1 , 0 0 0 
 
5 0 0 
 
0 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-14 PGE2 Enhances IL-1β Release after 4h, but not 5’ Stimulation. IL-1β measurements by ELISA of 
supernatant samples from BMDMs treated for 3.5 hours or 5 minutes with LPS (100ng/ml) and/or PGE2 (500nM) 
followed by 30 minutes of ATP (5mM). Statistics used one-way ANOVA with Bonferroni’s post-test. 
*P˂0.05,**P˂0.01, ***P˂0.001. 
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Chapter 4. 
 
Prostaglandin E2 inhibits neutrophil extracellular trap formation post-stem 
cell transplant 
4.1 Background 
 
Approximately 50,000 hematopoietic stem cell transplants (HSCTs) are 
performed annually (57% autologous; 43% allogeneic) 1. HSCT patients exhibit 
susceptibility to pulmonary infections even late post-engraftment 2-4. Neutrophil 
recruitment and function is important for innate immunity. In response to inhaled 
pathogens, neutrophils are recruited by chemotactic signals released from activated 
alveolar macrophages and epithelial cells 5. Chronic granulomatous disease (CGD) 
patients with mutations in the nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase complex exhibit functional defects in neutrophils [e.g. reduced formation of 
neutrophil extracellular traps (NETs)] that render them more susceptible to pathogens 
also afflicting HSCT patients, such as Streptococcus pneumoniae, Pseudomonas 
aeruginosa, and Aspergillus species 6, 7. Interestingly, CGD patients receiving gene 
therapy complementing NADPH oxidase function restore anti-Aspergillus responses via 
restored NETs 7, 8. 
Long term defects in neutrophil functions have previously been noted in HSCT patients 
6. Neutrophils from autologous HSCT patients exhibit a diminished capacity to produce 
respiratory burst 6, 9, 10 while allogeneic HSCT patients exhibit defects in neutrophil 
chemotaxis in addition to impaired respiratory burst 6, 11, 12. However, the cause for 
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neutrophil dysfunction has remained unclear. Furthermore, the ability of neutrophils 
from HSCT patients to undergo NETosis is unknown. 
NETosis is a cell death pathway characterized by release of extracellular web-like 
structures composed of chromatin, histones, and granular proteins 13-15. NETs serve as 
antimicrobial defenses against extracellular pathogens including bacteria 16. Takei et al. 
described this as a novel form of cell death, distinct from apoptosis and necrosis, due to 
its dependence on chromatin decondensation, increase in membrane permeability and 
its independence from necrosis-inducing or apoptosis-inducing stimuli 17, 18. Studies 
have shown NETosis may be dependent on NADPH oxidase or myeloperoxidase- 
generated reactive oxygen species, autophagy, neutrophil elastase, and histone 
citrullination by peptidylarginine deiminase 4 19-21. Live cells can also participate in a 
process called “vital NETosis” where neutrophils maintain their membrane integrity 
while rapidly releasing NETS and continuing to chemotax and phagocytize bacteria 22, 
23. 
We previously demonstrated that host defense against both Pseudomonas aeruginosa 
and Staphylococcus aureus is impaired following BMT in mice 24-26. As NETs can 
effectively kill both S. aureus and P. aeruginosa 14, 18, 27, it is unclear whether the 
bactericidal defects relate to impaired NETosis post-transplant. We showed defective 
neutrophil function is attributable to overproduction of PGE2 25. PGE2 is generated using 
cyclooxygenase (COX) enzymes (basal COX-1 or inducible COX-2) 28. Inhibition of 
COX with indomethacin rescued the functional bactericidal defects in vivo 25. Similar 
pathways can be involved in both intracellular killing and NETosis. NADPH oxidase 
activity and autophagy 29 can promote NETosis and killing, but regulation is poorly 
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understood. While much is known about inducers of NETosis (e.g. PMA, bacterial 
components, and IL-8), nothing is known of physiological inhibitors or negative 
regulators. Here, we propose a novel role for PGE2 as an inhibitor of NETosis. 
4.2 Results 
 
NETosis is impaired post-syngeneic (syn) and allogeneic (allo) BMT: To determine 
whether the capacity to undergo NETosis was deficient or intact following BMT, 
neutrophils were recruited into the lungs of untransplanted control or syn or allo BMT 
mice. We next examined NET formation following treatment with PMA or infection with 
S. pneumoniae. PMA, a known inducer of NETosis, stimulated NETs in untransplanted 
control neutrophils; however, PMA-treated syn and allo BMT neutrophils exhibited 
impaired extracellular DNA release as measured by extracellular Sytox fluorescence vs. 
controls (Fig.4-1A-B). These observations were supported by immunofluorescence that 
showed few visible NETs in untreated groups (Fig.4-1C top row), but extensive, intact 
NETs upon PMA stimulation in controls. In contrast, NETs from both syn and allo BMT 
cells were significantly decreased and appeared structurally less intact (Fig.4-1C bottom 
row). Defective NETosis was also noted in neutrophils from BMT mice exposed to S. 
pneumoniae, a relevant HSCT pathogen (Fig.4-1A).  We confirmed that neutrophils 
from syn BMT mice exhibited basal defects in production of hydrogen peroxide (Fig.4- 
1D). 
COX inhibitors restore NET formation post-BMT: To determine whether NETosis 
was negatively regulated by increased COX-2 activity, syn BMT mice were 
intraperitoneally injected with indomethacin, a non-selective COX inhibitor prior to the 
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recruitment of neutrophils. Following in vivo inhibition of COX, NETosis was restored in 
neutrophils from syn BMT mice (Fig.4-2A). In vivo treatment with indomethacin did not 
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Figure 4-1: NETosis is impaired post-syn and allo BMT. LPS-recruited neutrophils from the lung of (A) syn BMT or (B) allo 
BMT and untransplanted control mice were stimulated for 5 h with PMA (100 nM), S. pneumoniae (MOI: 5), or left untreated and 
NETosis was measured by Sytox Green fluorescence. (C) NETosis following 5 h PMA treatment in LPS-recruited neutrophils 
from untransplanted control, syn BMT, and allo BMT mice was visualized by immunofluorescence via staining of DNA (Hoechst, 
blue) and neutrophil elastase (green, control and syn BMT 20x; allo BMT 40x magnification; arrowheads denote NETs in BMT 
groups). (D) Lung neutrophils were harvested 18-20h post-LPS intratracheal injection and H2O2 production was measured 
colorimetricly via the Amplex Red reagent; *P<0.05, **P <0.01, ***P <0.001, ****P <0.0001 relative to control. In panel A, n=6 
/group for media and PMA stimulations and n=3/group for S. pneumoniae stimulation; in panel B, n=3/group; in panel D, the 
n=15/group 
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affect neutrophil recruitment as LPS exposure recruited 89±1.77% neutrophils in syn 
BMT receiving indomethacin which was comparable to the 88.7±1.34% neutrophils 
recruited in untreated control and 87.1±1.32% in vehicle-treated syn BMT mice. 
Immunofluorescence studies again confirmed the stimulatory effects of indomethacin on 
NETosis, as in vivo inhibition of COX visibly enhanced NET production from syn BMT 
neutrophils compared to untransplanted control neutrophils (Fig.4-2C). NETosis was 
increased in allo BMT mice upon in vitro COX inhibition with indomethacin (Fig.4-2B). 
The ability of PMA to induce NETs in syn BMT mice was also restored by diclofenac, an 
inhibitor with higher affinity for COX-2 than COX-1, or by addition of anti-PGE2 (Fig.4- 
3A-B). Similarly, neutrophils from mice deficient in PGE synthase showed enhanced 
PMA-induced NETosis compared to cells from wild-type mice (Fig.4-3C). 
PGE2 inhibits PMA-induced NETs from murine and human neutrophils: Neutrophils 
from BMT mice have elevated levels of cytosolic phospholipase A2 and COX-2 (Fig.4-4). 
PGE2 causes functional defects in alveolar macrophages and neutrophils that occur 
post-BMT 25, 26, 30.  Thus, we focused on the effects of PGE2 on NETosis. Interestingly, 
in vitro treatment with PGE2 was able to decrease NET release from control murine 
neutrophils despite stimulation with PMA (Fig.4-5A). This effect was reversed in the 
presence of anti-PGE2 antibodies (Fig.4-5B). PGE2 was also able to inhibit NETosis in 
cells from normal volunteers (Fig.4-5C). Activation of the COX pathway in syn BMT 
mice results in ~4 ng/ml (11.34 nM) PGE2 in the BALF25 and elevated levels are also 
seen in HSCT BALF (Fig.4-4B). Figure 3D demonstrates that physiologic levels of 
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PGE2 (10 nM) are sufficient to limit PMA-induced NETosis in a control subject. 
Immunofluorescence studies showed a significant absence of intact NET formation 
upon the simultaneous treatment of human or murine neutrophils with PMA and PGE2 
(Fig.4-3E). 
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Figure 4-2: Indomethacin rescues impaired NETosis post-BMT. LPS-recruited pulmonary neutrophils from 
untransplanted control, syn BMT, or syn BMT mice following i.p. injection with indomethacin (1.2 mg/kg) were treated with 
PMA (100 nM) or left untreated for 5 h and NETosis was measured via (A) Sytox fluorescence or (C) immunofluorescence 
studies (gray scale of Hoechst DNA staining at 20x magnification; arrowheads denote NETs). (B) Sytox fluorescence was 
performed in LPS-recruited allo BMT neutrophils to measure NETosis following 5 h in vitro treatment with indomethacin (10 
µM), PMA (100 nM), PMA and indomethacin, or media alone; *P <.05, **P <.01, ***P <.001. In panels A and B, n=4/group. 
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PGE2 signaling inhibits NETosis via both PKA- and Epac-mediated pathways: 
PGE2 signals through EP receptors 1-4 and we previously showed that both EP2 and 
EP4 were enhanced on BMT neutrophils when compared to their respective levels on 
control cells [25 and inset in Fig.4-6A]; however, it should be noted that EP2 levels are 
still higher than EP4 levels on BMT neutrophils when compared to each other (Fig.6A, 
large graph). To determine whether EP2 signaling regulated NETosis, BMT neutrophils 
were treated with an EP2 receptor antagonist (PF-04418948). Treatment with the EP2 
antagonist enhanced NETosis in both syn and allo murine BMT neutrophils (Fig.4-6B- 
C). As EP2 and EP4 signal through PKA and/or Epac 31-33, the effects of PKA- or Epac- 
agonists on NETosis were analyzed. Activation of either the PKA or Epac pathway was 
able to effectively block NET production (Fig.4-6D). 
Blocking PGE2 signaling rescues NETosis in allogeneic HSCT patients: We next 
investigated the effects of EP receptor antagonism on NETosis in neutrophils from the 
peripheral blood (Fig.4-7A-C) or bronchoalveolar lavage (Fig.4-7B) of allogeneic HSCT 
patients. Blocking EP2 or EP4 signaling enhanced NET formation in HSCT samples. 
Healthy human peripheral blood neutrophils were treated with PMA, PKA agonist, Epac 
agonist, or a combination of these treatments. Similar to our murine data, PMA was 
able to induce NETs and this function was decreased by concurrent treatment with PKA 
agonist or the Epac agonist (Fig.4-8A). In HSCT patients, as expected PMA did not 
significantly induce NETs alone, but was able to in the presence of a PKA antagonist 
(Fig.4-8B). The Epac antagonist was toxic in the HSCT neutrophils (data not shown). 
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PGE2 inhibits autophagy-induced NET release: The mechanism(s) by which NETs 
are released into the extracellular space may involve autophagy as well as reactive 
oxygen species, myeloperoxidase (MPO), and neutrophil elastase expression 29. In 
support of this, PMA treatment can stimulate NADPH oxidase activity and autophagy 34. 
Autophagy has been shown to play an important role in promoting clearance of 
intracellular pathogens 35. In the presence of nutrients, mammalian target of rapamycin 
(mTOR) functions to inhibit autophagy 36. Rapamycin, an mTOR inhibitor, promotes 
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Figure 4-3: Diclofenac or anti-PGE2 can rescue NETosis post-BMT and mPGES -/- mice have enhanced NETosis. 
A) LPS-recruited pulmonary neutrophils were isolated from syn BMT mice or syn BMT mice treated with diclofenac (30 
mg/kg in saline) and were then cultured in the presence of media alone (mock), PMA (100 nM) or PMA + anti-PGE2 for 5 
h and NETosis was measured via Sytox fluorescence (SF). B) LPS-recruited neutrophils isolated from control, syn BMT 
or syn BMT mice treated with diclofenac were collected and total RNA was isolated. qRT-PCR was used to analyze 
expression of COX-2. C) LPS-recruited neutrophils from WT and PGE synthase (mPGES)-/- mice were treated with 
media or PMA as above and NETosis was measured by SF; *P <.05, **P <.01, ****P<0.0001, ns=not significant. 
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NET release in neutrophils from control mice but not in cells from syn BMT mice (Fig.4- 
9A), suggesting impaired autophagy-mediated NETosis post-transplant. Treatment with 
PGE2 conferred defective NET release in control murine neutrophils despite 
concomitant stimulation with rapamycin (Fig.4-9B). This inhibition was corroborated by 
western blot analysis as less MPO was detected in the supernatant of rapamycin plus 
PGE2 –treated neutrophils than was released from cells treated with rapamycin alone 
(Fig.4-9C). Furthermore, EP2 receptor antagonism restored rapamycin-induced NET 
formation in syn BMT lung neutrophils (Fig.4-9D). 
 
 
 
 
 
Ratio: 1.01 1.64 
 
 
Figure 4-4: BMT neutrophils have elevated cPLA2 and COX-2 levels and human BALF post-HSCT has 
increased PGE2 levels. A) LPS-recruited neutrophils were collected from untransplanted control mice or syn BMT 
mice and Western lysates were prepared for analysis of cPLA2 and COX-2. Expression was compared to levels of β- 
actin protein in cells. Shown are representative blots from one mouse, representative of data from 3 animals. B) 
BALF that had been collected from n=22 HSCT patients and n=8 normal volunteers as part of a long term follow up 
study on HSCT patients were analyzed for levels of PGE2 by ELISA, p=0.0025. 
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Figure 4-5: PGE2 inhibits PMA-induced murine and human NETs. (A) Murine neutrophils were stimulated with PGE2, PMA, combination or 
with (B) anti-PGE2 for 5 h and measured for NETosis via Sytox fluorescence (SF). (C) Human neutrophils were stimulated with PMA, PGE2, PMA 
+ PGE2 or (D) 10nM PGE2 or were left untreated for 3h before NETosis was measured by SF or (E) immunofluorescence. (Hoechst, DNA, blue; 
neutrophil elastase (green); 60x magnification; arrowheads denote NETs); *P <0.05, **P <0.01, ***P<0.001, ****P <0.0001. 
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NETosis is dependent on both NADPH oxidase and autophagy 29, so we next 
modulated these pathways in neutrophils collected from the bone marrow of control 
mice. PMA effectively induced NET release from bone marrow neutrophils, a process 
significantly inhibited following inhibition of autophagy (wortmannin treatment) or 
inhibition of reactive oxygen species (diphenyleneiodonium (DPI) treatment) (Fig.4- 
9E).Interestingly, when examining rapamycin-induced NETosis, PGE2 was more 
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effective in limiting this pathway than either wortmannin or DPI treatment (Fig.4-9F). 
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Figure 4-6: Inhibition of PGE2 signaling rescues murine NET production post-BMT. (A) Total RNA was isolated from 
neutrophils collected from control and syn BMT mice (n=6 per group) and real-time RT-PCR was performed to analyze 
expression of EP2 and EP4 receptors. Inset shows levels of EP2 and EP4 in BMT samples compared to their respective 
levels in cells from control untransplanted mice (normalized to 1). The large panel shows the levels of EP4 when compared to 
EP2 (normalized to 1) in the syn BMT cells alone. LPS recruited neutrophils were collected from (B) syn (n=5-6/group) and 
(C) allo (n=4-5/group) BMT mice were treated with PMA (100 nM), an EP2 antagonist (EP2 anta; 10 nM), or PMA and EP2 
anta for 5 h and NETs were measured by Sytox fluorescence. (D) Effects of downstream PGE2 signaling on NETosis were 
determined with 5 h PKA agonist (PKA ag=6-Bnz-cAMP; 500 µM) and Epac agonist (EPAC ag=8-pCPT-2’-O-Me-cAMP; 500 
µM) treatment plus or minus PMA on untransplanted control neutrophils. NET production was determined by Sytox 
fluorescence (n=4-6 pooled from 2 separate experiments; shown as “percent of control”); *P <0.05, **P <0.01, ***P <0.001. 
 
When neutrophils from an age-matched control and HSCT patient were collected and 
analyzed on the same day, the cells from the HSCT patient were defective in NETosis 
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induced both by PMA and rapamycin relative to the control subject (Fig.4-10A). In 
human control neutrophils, rapamycin effectively induced NETosis (Fig.4-10B). This 
rapamycin-stimulated NETosis was reduced by PGE2, PKA agonists or Epac agonists 
(Fig.4-10B). 
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Figure 4-7: Blocking EP receptor signaling rescues NETs in allogeneic HSCT patients. Neutrophils collected from peripheral 
blood (A and C) or BAL (B) from allo HSCT patients were incubated with media, PMA (100 nM), EP2 antagonist (10 nM), or EP4 
antagonist (AE3-208, 1µM) as indicated and NETosis was measured by Sytox fluorescence. Panel A reports the mean ± 95% CI as 
estimated via mixed effect linear models for n=5 HSCT patients and panel C reports data from n=6 HSCT patients (see supplemental 
table S1C). *P <0.05, **P <0.01, ****P <0.0001. 
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Overall, these data suggest that the inhibition of NETs by PGE2 signaling is a universal 
feature of neutrophils obtained from both lung and bone marrow compartments in mice 
and from lung and peripheral blood of humans. In addition, PGE2 can inhibit NETosis 
induced by a variety of stimuli. 
4.3 Discussion 
 
Neutrophil responses have been shown to be particularly important for host 
response to pulmonary infection. We have previously shown that neutrophils are unable 
to clear engulfed pathogens post-BMT 25. Here we show that neutrophils recruited to the 
lung also exhibit impaired NETosis following either syngeneic or allogeneic BMT 
implying that extracellular killing mechanisms may also be defective post-BMT. This 
impairment is caused by overproduction of PGE2 and signaling via the EP2 or EP4 
receptor. We verified the ability of physiologic doses of PGE2 to limit NETosis and 
utilized anti-PGE2 antibodies to confirm specificity. We previously measured EP4 
receptor expression to be 4.8-fold higher in BMT PMNs while EP2 was 2.4-fold higher 
compared to untransplanted controls [inset Fig. 4-6A 25]. EP4 has higher affinity for 
PGE2 than does EP2 (0.79 nM vs 4.9 nM) 37, but given the fact that EP2 levels are over 
4-fold higher than EP4 levels (Fig.4-6A large panel) when compared to each other on 
BMT neutrophils and both of these receptors signal via a cAMP intermediate, it is not 
surprising that both EP2 and EP4 antagonists are effective in restoring NETosis post- 
transplant. We were only able to obtain one BALF sample with sufficient neutrophils for 
analysis, but BALF-derived cells behaved similarly to peripheral-blood derived cells from 
other HSCT patients in responses to EP2 antagonists (Fig.4-7A-B). While it is possible 
that other changes in the lung post-BMT (e.g. elevated IL-6 and GM-CSF; decreased 
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TNFα, IFN-γ, and leukotrienes) 24, 30, 38, 39 or other COX-2 effectors (e.g. thromboxane 
and prostacyclin) may also serve roles in regulating NETosis, our studies prove that 
PGE2 signaling limits NETosis. 
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Figure 4-8: Alterations in PGE2 signaling can influence NETosis in Control and HSCT patients. Neutrophils were 
collected from peripheral blood of 4 normal subjects (A) or from 8 HSCT patients (B). Cells were cultured in the presence of 
media, PMA (100 nM), Epac agonist (EPAC ag, 8-pCPT-2’-O-Me-cAMP; 500 µM), PKA agonist (PKA ag, 6-Bnz-cAMP; 500 µM) 
or PKA antagonist (H89, 20 µM; Sigma) as indicated for 3 hours and NETosis was measured by Sytox fluorescence; 
***P<0.001, ****P <0.0001. Graphs represent the mean ± 95% CI as estimated via mixed effect linear models (see supplemental 
tables S1D and S1E). 
 
 
As PGE2-EP2 or PGE2-EP4 intracellular signaling relies on PKA and/or Epac 40, we 
explored the contribution of both pathways in NET regulation. Interestingly, the use of 
either PKA or Epac agonists was sufficient for the inhibition of NETosis in murine and 
human cells and the use of both agonists did not result in an additive effect. Similar 
inhibitory effects of PGE2 on NETosis were observed regardless of source of 
neutrophils (BAL or peripheral blood) or species (humans or mice) or stimulus (PMA, 
rapamycin, bacteria), suggesting that this is a well-conserved mechanism. It is 
interesting that the neutrophils collected from allogeneic HSCT patients showed 
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spontaneous NETosis following treatment with EP2 or EP4 antagonists alone (Fig.4-7) 
which may indicate that cells from these patients were stimulated in vivo, yet unable to 
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Remijsen et al. previously showed that autophagy was required for the productive 
release of NETs 29. Our data demonstrate that recruited lung neutrophils from 
untransplanted control mice as well as neutrophils isolated from murine bone marrow or 
normal volunteers induce NET formation following stimulation of autophagy via 
F 
** 
** 
D 
A 
Figure 4-9: PGE2 inhibits autophagy-induced murine NETosis. (A) LPS-recruited lung neutrophils of untransplanted control and syn 
BMT mice were treated with 200 nM rapamycin or were left untreated for 5 h prior to Sytox fluorescence detection; n=6/group. (B) LPS- 
recruited lung neutrophils from untransplanted control mice were treated with 10 µM PGE2, rapamycin, or rapamycin + PGE2 for 5 h prior 
to Sytox fluorescence detection; n=6/group. (C) LPS-recruited lung neutrophils of untransplanted control mice were stimulated with 
rapamycin, rapamycin + PGE2, or were unstimulated for 5 h prior to removal of supernatants and western blot analysis of this supernatant 
for myeloperoxidase. The western blot depicts dividing lines to denote altered lane order from the original blot. (D) LPS-recruited lung 
neutrophils from syn BMT mice were treated with EP2 antagonist (10 nM), rapamycin, rapamycin +EP2 antagonist, or were untreated for 
5 h prior to detection of Sytox fluorescence, n=6/group. (E) Bone marrow neutrophils from control mice were treated with PMA, PMA + 
wortmannin (100 nM), or PMA + diphenyleneiodonium (DPI; 10 µM) for 5 h prior to Sytox measurement, n=5/group. (F) Bone marrow 
neutrophils from control mice were treated as above with media, PGE2, wortmannin, DPI or combinations of these drugs with rapamycin 
for 5 h prior to detection of Sytox fluorescence, n=5-8/condition. *P <0.05, **P <0.01, ***P <0.001, ****P <0.0001. 
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rapamycin (Fig.4-9B,F and 4-10B); however, NETosis was defective in syn BMT lung 
neutrophils despite exposure to rapamycin (Fig.4-9D). When cells from a control and 
HSCT patient were analyzed simultaneously, the response to rapamycin was 
diminished in the HSCT sample relative to the control (Fig.4-10A). There were 
differences in the collection of the cells as murine neutrophils recruited to the lung were 
exposed to LPS prior to treatment with rapamycin whereas murine bone marrow and 
human peripheral blood neutrophils are unstimulated. LPS alone can induce NET 
formation 14, 18, however it is likely that not all neutrophils produce NETs following the 
initial recruitment with LPS as our studies with murine lung neutrophils show clear 
changes in NET release following treatments. Furthermore, the fact that rapamycin was 
sufficient to induce NETs from human neutrophils in the absence of any priming 
factors, like fMLP, suggests that autophagy induction is sufficient to induce NET 
release, challenging findings from a previous study 29. 
Hydrogen peroxide, a reactive oxygen species (ROS), was decreased in syn BMT 
neutrophils. As ROS production is required for NETosis, it is possible that PGE2- 
dependent inhibition of NETosis is mediated through the Epac-mediated inhibition of 
ROS. Recently, a renal ischemia-reperfusion study found that activation of Epac 
reduced mitochondrial ROS production via interaction with Rap1 in tubular epithelial 
cells 41. Thus, it is possible that Epac signaling upstream of NAPDPH oxidase or 
mitochondrial ROS production mediates inhibition of NETs. Alternatively, the effect of 
PGE2 and Epac on autophagy is unknown. However, previous studies have shown a 
possible role for PKA in autophagy inhibition via phosphorylation of LC3 42 or activation 
of TORC143. Thus, it is possible that BMT neutrophils exhibit defective NETosis as a 
100 
 
consequence of reduced autophagy and/or ROS production secondary to PGE2 
stimulation. These pathways are likely linked, and this may also explain why inhibition of 
either PKA or Epac restored NETosis post-transplant. 
Previous studies from our lab demonstrated that blocking EP2 signaling improves lung 
alveolar macrophage function post-HSCT by restoring bactericidal killing 25. Our current 
study extends this work to suggest that EP2 or EP4 antagonists may also restore both 
intracellular and extracellular killing mechanisms in neutrophils post-transplant. It is 
worth noting that the EP2 and/or EP4 antagonists or PKA antagonists restored function 
to neutrophils of HSCT patients despite the fact that these patients were often on 
immunosuppressive medications (Table 1). Thus, this strategy may be a way to 
improve innate immune function while maintaining immunosuppressive control of graft 
vs. host disease. A limitation of our study is that the sample size for the human studies 
is small; however, findings were highly reproducible between mice and humans, and all 
findings are consistent with our conclusion that PGE2 signaling inhibits NETosis. 
Another implication of our work is that there may be a therapeutic role for EP2 or EP4 
agonists for the inhibition of pathological NETosis in diseases where uncontrolled NET 
formation induces exacerbation of disease 44-46. Currently, therapies under development 
or in use for targeting NETs in autoimmune diseases like Lupus include DNase 47, 48, 
anti-histone antibodies 49, 50, and anti-proteases 51. In the case of anti-histone 
antibodies, the possibility of promoting autoimmunity may outweigh the benefits of this 
therapy. Prior to our studies, physiological factors aside from DNase that could 
potentially suppress NETosis were unknown. Here, we reveal PGE2 signaling via EP2 
or EP4 as a negative regulator of NETosis. 
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Figure 4-10: PGE2 regulates NETosis induced by autophagy in human neutrophils. (A) Human peripheral blood neutrophils from 
control subject 5 (age 50) and HSCT 2 (age 47) were collected on the same day and stimulated for 3 h in the presence of media, PMA 
(100nM) or rapamycin (200 nM) before being analyzed by Sytox fluorescence, n=10 replicates per patient per group. (B) Peripheral blood 
neutrophils collected from 4 normal volunteers were cultured for 3 h in the presence of media, PGE2 (10 µM), the Epac agonist (EPAC ag, 
8-pCPT-2’-O-Me-cAMP; 500 µM), PKA agonist (PKA ag, 6-Bnz-cAMP; 500 µM), or combinations of these agents with rapamycin (200 nM) 
for 3 hours prior to Sytox detection; *P <0.05, ****P <0.0001. 
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Table 4-1: Human Subject Characteristics 
 
 
Subje 
ct ID 
Ag 
e 
Gende 
r 
HSC 
T 
Type 
Days 
post- 
HSC 
T 
Indication for 
HSCT 
Conditioni 
ng   
Regimen 
Chroni 
c   
GVHD 
? 
Current 
Immunosuppressi 
ve Regimen 
HSCT 
1   
(BALF) 
65 M Allo 806 Acute 
Myelomonocy 
tic Leukemia 
Fludarabine 
and 
Busulfan 
Presen 
t 
Dexamethasone 
Prednisone 
HSCT 
2 
47 F Allo 158 Acute 
Myelomonocy 
tic Leukemia 
Fludarabine 
and 
Busulfan 
Absent Tacrolimus 
HSCT 
3 
64 F Allo 616 Acute Myeloid 
Leukemia 
Fludarabine 
and 
Busulfan 
Presen 
t 
Predinosone 
HSCT 
4 
70 F Allo 58 Myelodysplast 
ic Syndrome 
Fludarabine 
and 
Busulfan 
Absent Tacrolimus 
Methotrexate (low 
dose) 
HSCT 
5 
63 F Allo 91 Myelofibrosis Fludarabine 
and 
Busulfan 
Absent Tacrolimus 
Prednisone 
HSCT 
 
6 
67 M Allo 20 Acute Myeloid 
 
Leukemia 
Clofaradine 
 
Bulsufan 
Absent Tacrolimus 
 
Cellecept 
HSCT 
7 
30 M Allo 176 Acute Myeloid 
Leukemia 
Fludarabine 
and 
Busulfan 
Absent Tacrolimus 
Restasis 
110  
HSCT 
8 
27 M Allo 26 T cell Acute 
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5 
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6 
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Chapter 5. Discussion 
 
5.1 Elevated PGE2 post-BMT mediates IL-1β-related acute lung injury (ALI) 
 
HSCT transplant patients are susceptible to opportunistic bacterial infections particularly 
with Pseudomonas aeruginosa. This Gram-negative bacterium has been shown to 
cause much of its lung pathology by inducing IL-1β-dependent acute lung injury (ALI)1. 
PGE2 is elevated in HSCT patients and reducing its levels has shown improvement in 
clearance of P. aeruginosa2, 3. Yet, the role of PGE2 in regulating IL-1β was not well 
understood. Thus, in chapter 3 of this dissertation, I aimed to study the role of PGE2 in 
IL-1β related lung injury caused by P. aeruginosa. Using a BMT mouse model 
(described in chapter 1), I detected a more severe ALI, and more bacterial burden in 
BMT mice compared to control mice4. Interestingly, using an LPS-induced ALI model, I 
determined that the severe ALI in BMT mice was not dependent on the increased 
bacterial burden, but rather, it was dependent on excessive secretion of IL-1β. 
Moreover, I found that IL-1β release did not just correlate with elevated levels of PGE2, 
but also, PGE2 dependent stimulation of the EP2/EP4 receptors in alveolar 
macrophages (AMs) was responsible for the exacerbated IL-1β pathology. 
Furthermore, I performed treatments with a non-selective COX-inhibitor, indomethacin, 
in BMT mice and observed reduced lung injury, less IL-1β and improved bacterial 
clearance. These findings suggest ideas for the development of new therapeutic 
strategies to improve outcomes of HSCT patients with pulmonary infections with P. 
aeruginosa. However, the translatability of our findings is limited for multiple reasons 
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including use of our mouse model and choice of experimental reagents as discussed 
below. Such limitations should be addressed before fully considering this pathway as a 
therapeutic target. 
One of the limitations in the work performed in chapter 3 is that all murine experiments 
were in syngeneic BMT models, where total body irradiation (TBI) was used for 
conditioning, 5x106 total bone marrow cells were infused to reconstitute the immune 
system, and all experiments were performed at 5 weeks post-transplant (post- 
engraftment phase). To a large extent, these BMT mice replicate the 
immunosuppression to bacterial infections and the elevated levels of PGE2 found in 
humans post-HSCT5 making it a good system to study post-transplant infections; 
however, around 47% of transplants performed each year are allogeneic6. Thus, the 
findings in this dissertation should be reproduced or tested using an allogeneic BMT 
murine model. Additionally, in the clinics, TBI is not the standard conditioning given to 
all HSCT patients. The conditioning regimen will depend on the disease. Combinations 
of chemotherapy and TBI are mostly given to the patients’ pre-transplant7. Research in 
the laboratory of my advisor has shown differences in lung and spleen immune 
reconstitution post-TBI or chemotherapy. It was reported that mice (C57BL/6J) exposed 
to 13Gy of TBI prior to BMT have an immune reconstitution of 95% donor cells in the 
spleen and around 81% donor cells in the alveolar compartment8; whereas 
chemotherapy performed by busulfan and cyclophosphamide treatment lead to an 
immune reconstitution of 72% spleenocytes from donor cells and 57% of alveolar cells 
from donor sources8. Both conditioning regimens lead to elevated levels of PGE2 
secreted by AMs, and AMs were defective in bacterial phagocytosis8. Thus, we can 
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hypothesize that elevated levels of PGE2 in the lung, independent of the conditioning 
regimen, would exacerbate IL-1β related ALI. However, findings discussed in chapter 3 
should be replicated in a BMT mouse model where different conditioning regimens 
including chemotherapy are performed. 
As mentioned before, our findings show that improved bacterial clearance in BMT mice 
can be achieved by decreasing the levels of PGE2. These experiments were all 
performed with P. aeruginosa infected mice, and no other bacteria were used in vivo. 
My focus was on P. aeruginosa because it is one of the main pathogens affecting HSCT 
individuals, and this bacterium is now considered to be a critical public threat. However, 
multiple bacteria can present lung complications in HSCT individuals including 
methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae5, 9- 
11. In chapter 3, using in vitro assays, I was able to demonstrate that PGE2 can 
exacerbate IL-1β release when cells are challenged with MRSA and S. pneumoniae 
suggesting that exacerbated IL-1β is not pathogen specific, and it can also occur 
without stimulation of the Gram-negative sensor, TLR4, as both MRSA and S. 
pneumoniae are gram-positive bacterium. Yet, to make inhibition of PGE2 a global 
treatment to combat bacterial infections, we should perform MRSA and S. pneumoniae 
infections, along with other bacteria, in BMT mice and test the ability of PGE2 signaling 
inhibitors to decrease bacterial burden. Apart from bacterial infections, PGE2 has been 
reported to play both positive and negative roles in the outcome of multiple viral and 
fungal pathogens12. So implications of blocking PGE2 in HSCT subjects may go beyond 
bacterial pathogens, and extend to all pathogens whose pathology is known to be 
regulated by PGE2. However, we would not expect that inhibition of PGE2 in HSCT 
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would confer protection to all pathogens. For example, additional work in the laboratory 
of my advisor has shown that BMT mice have impaired immunity to gamma 
herpesvirus, but this was independent of high levels of PGE213, 14. However, HSCT 
patients are highly susceptible to infections with fungal pathogens including Candida 
albicans and the pathology caused by this pathogen is known to be partially regulated 
by PGE215. Thus, we can hypothesize that inhibition of PGE2 may also play a positive 
role in BMT subjects post-C. albicans infection. Thus, it would be of high importance to 
test inhibition of PGE2 in BMT mice infected with not just bacterial pathogens, buy also 
fungal and viral pathogens. 
An additional limitation of our findings is the sole use of the non-selective COX inhibitor, 
indomethacin, in P. aeruginosa infected mice to reduce PGE2. Indomethacin will not just 
reduce the levels of PGE2 but also other COX metabolites, which might also be playing 
a role in P. aeruginosa pathogenesis. P. aeruginosa lung infection in mice has been 
shown to dysregulate levels of eicosanoids including elevating levels of PGE2 and 
prostacyclin (PGI2). This is due to the expression of a type three secretion system 
effector molecule, ExoU, a homologue of phospholipase A2 16. ExoU is a marker of high 
virulence in P. aeruginosa17. Previously, the laboratory of my advisor showed that PGI2 
is also found elevated in BMT mice8. As our approach to reduce PGE2 is also affecting 
all COX metabolites including PGI2, future experiments should focus on using specific 
PGE2 signaling inhibitors. Additionally, experiments should also address the effect of 
PGI2, in vivo, post-P. aeruginosa infection in BMT mice. 
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5.2 PGE2 mediated IL-1β increase is dependent on EP2/EP4 signaling and 
activation of CREB 
In chapter 3, we demonstrated that PGE2 stimulation in murine macrophages and 
human monocyte-derived macrophages lead to increased IL-1β transcript levels. This 
serves as “signal 1” of inflammasome-mediated IL-1β secretion which is normally 
restricted to pathogen recognition receptors (PRRs) including toll-like receptors 
(TLRs)18. Signal 2 of IL-1β secretion is mediated by a wide array of signals leading to 
activation of caspase-1 and one or multiple members of the inflammasome family 
(NLP3, NLRC4, etc.). Some stimulations such as LPS can lead to both signal 1 and 2. 
For example, we can achieve increased IL-1β secretion in macrophages, in vitro, with 
prolonged LPS stimulation. Prolonged stimulation with LPS doesn’t just lead to a TLR4- 
dependent increase in pro-IL-1β, but also to a moderate activation of caspase-119; thus, 
activating both signal 1 and signal 2 for IL-1β secretion. This is an effect unique to 
murine macrophages as only signal 1 is necessary for IL-1β secretion in human 
monocytes, probably because of the constant expression of caspase-120, 21. Single 
stimulation with PGE2 did not affect caspase-1. To understand how PGE2  was 
mediating the increase in pro-IL-1β, we decided to focus on the PGE2 signaling 
pathway. PGE2 can signal through 4 different G-protein-coupled receptors termed EP1- 
EP412. The mechanism that we found to contribute to this increase was activation of 
cAMP-PKA by stimulation of EP2 and EP4 receptors, and not the EP3 receptor. 
However, we did not test the EP1 receptor as we were lacking a specific agonist for 
 
EP1 that would not activate other EP receptors. Hence, the role of EP1 in PGE2 
dependent increased IL-1β should be addressed. Nevertheless, we do not anticipate an 
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increase in IL-1β expression post-EP1 stimulation. This is because our data suggest 
that IL-1β increase is mediated by the activation of PKA and not by the EP1 intracellular 
signaling pathway mediators, calcium and protein kinase C (PKC). PKA stimulation 
leads to the activation of two downstream transcription factors, NFκB and CREB22. We 
demonstrated that inhibition of the transcription factor CREB, with the use of a selective 
antagonist, was able to abolish the increase in IL-1β. Thus, we concluded that CREB 
was the main transcription factor necessary for PGE2-dependent IL-1β increase. 
However, we never tested the role of the master transcription factor, NFκB. 
Interestingly, shortly before we published our findings, another research laboratory 
reported that PGE2 increases IL-1β production23. They attributed this increase to 
activation of NFκB dependent on EP2/EP4 stimulation. Thus, CREB might not be the 
only transcription factor playing a role in increasing levels of IL-1β post-EP2/EP4. If our 
results are taken together with the other laboratories, both NFkB and CREB are likely 
involved. 
5.3 Improving bacterial clearance post-IL1β inhibition 
 
As mentioned before, in the lung of BMT mice, P. aeruginosa induces exacerbated 
levels of IL-β secreted mainly by AMs leading to ALI and high mortality. As we 
demonstrated that increased levels of PGE2, in BMT mice, regulated the exacerbated 
levels of IL-1β post- P. aeruginosa infection, we hypothesized that reducing PGE2 would 
further reduce the levels of IL-1β in the lung which would in turn reduce ALI. In 
accordance with our hypothesis, we detected less ALI and less IL-1β after indomethacin 
(non-selective COX inhibitor) treatments in P. aeruginosa infected BMT mice. 
Additionally, not to our surprise, we detected improved bacterial clearance. While PGE2 
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can regulate IL-1β secretion, it also participates is multiple pathways of inflammation 
and immunity. Thus, the improved bacterial clearance post-indomethacin treatment can 
be due to the many immunosuppressing effects that PGE2 has on immune cells 
including, but not limited, to inhibition of autophagy, NETs, phagocytosis and ROS 
production rather than inhibition of IL-1β. However, others have shown that inhibition of 
IL-1β specifically, independent of PGE2 inhibitors, can lead to improved P. aeruginosa 
clearance. For example, Il1R1-/- mice and administration of neutralizing antibodies to IL- 
1β can improve bacterial clearance against P. aeruginosa in the lung 1, 24. The reasons 
behind improved bacterial clearance post-IL-1β neutralization are not well understood. It 
is worth noting that specific inhibition of other cytokines including IL-18, TNF-α and IL- 
36 cytokines 1, 25, 26 have also been shown to improve P. aeruginosa clearance in the 
lung. These findings suggest that reducing inflammation seems to be an efficient 
method to improve P. aeruginosa clearance in the lung and might not be specific to one 
cytokine including IL-1β. Thus, the improved P. aeruginosa clearance post-IL1β 
inhibition might be due to reduced inflammation rather than an IL-1β specific effect on 
immune cells. 
5.4 Control of IL-1β by PGE2 
 
PGE2 is involved in many physiological processes and plays a role in both pro and anti- 
inflammatory responses by regulating different inflammatory mediators including 
cytokines27, 28. IL-1β is a pro-inflammatory cytokine that plays an essential role in 
controlling immune responses to pathogens. However, if not regulated, elevated levels 
of IL-1β can be pathologic as it has been reported in the lung post-P. aeruginosa 
infection29. Hence, our findings showing that decreasing PGE2 can lead to decreased 
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IL-1β-mediated pathology post-P. aeruginosa infection are of great clinical interest. 
However, our in vivo therapeutic approach to reduce PGE2 was using a COX-inhibitor, 
which will not just decrease the levels of PGE2, but also all COX metabolites including 
other prostaglandins (PGD2, PGI2, and PGF2α) and thromboxane A2. Thus, we cannot 
completely attribute decreased IL-1β to decreased PGE2. To overcome this limitation, 
future experiments should focus on specifically inhibiting PGE2 and measuring the effect 
on IL-1β. We could perform this experiment with the use of a selective EP2/EP4 
antagonist in vivo23. Additionally, decreasing inflammation by a COX inhibitor might 
affect multiple cytokines, not just IL-1β. Thus, future experiments should focus on using 
IL-1β specific inhibitors such as Anakinra and or neutralizing IL-1β monoclonal and 
polyclonal antibodies in BMT mice post P. aeruginosa infection to determine the specific 
role of IL-1β. 
5.5 AMs post-BMT mediate IL-1β related pathology post-P. aeruginosa infection 
Secretion of IL-1β by AMs post-P. aeruginosa infection has been shown to create lung 
pathology1. In our BMT mice, we were able to detect that AMs, but not interstitial 
macrophages, were responsible for elevated levels of IL-1β and we attributed this to 
increased COX-1 and COX-2 expression in this cell type. However, neutrophils have 
been reported to secrete high levels of IL-1β post lung bacterial infection30. We did not 
address the role of neutrophils in secreting IL-1β post-BMT. To address this issue, 
future experiments should focus on depleting AMs before bacterial challenge in BMT 
mice. We can achieve this by treating BMT mice with clodronate liposomes which will 
deplete AMs1. If we can still detect exacerbated levels of IL-1β post-bacterial infection in 
BMT mice it will mean that AMs are not the main source of IL-1β but rather other 
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immune cells such as neutrophils can also contribute. Additionally, we can measure IL- 
1β in the lung of BMT mice post-bacterial challenge with or without neutrophil depletion 
with anti-Ly6G antibodies. If we reduce the levels of lung infiltrating neutrophils, and still 
detect the elevated levels of IL-1β, we can clearly attribute exacerbated levels of IL-1β 
to AMs. 
5.6 PGE2 inhibits autophagy-mediated clearance of Pseudomonas aeruginosa 
Autophagy is an intracellular homeostatic process for energy conservation in which the 
cell engulfs cytoplasmic proteins and organelles for degradation31. It is characterized by 
formation of a double membrane vesicle termed an “autophagosome” which fuses with 
the lysosome to create the “autolysosome”, where engulfed material will be destroyed 
by lysosomal hydrolases32. Interestingly, autophagy has been shown to play a pivotal 
role in the destruction of invading microorganisms, control of inflammation, as well as an 
essential role in antigen presentation31. Autophagy can be induced in different ways 
including amino acid starvation, mammalian target of rapamycin (mTOR) inhibition, 
inflammatory cytokine stimulation, as well as PRR (e.g. TLR4) activation33-37. AMs, 
particularly, have been shown to primarily clear P. aeruginosa using autophagy 
machinery38. As explained in chapter 3, in our efforts to explain why PGE2 inhibits 
clearance of P. aeruginosa, we decided to study autophagy. We demonstrated that 
PGE2 stimulation in AMs was able to interrupt the autophagy-mediated killing of P. 
aeruginosa. The direct pathway of how PGE2 inhibits autophagy-mediated bacterial 
clearance was not determined, but the EP4-mediated activation of ERK1/2 signaling 
might explain autophagy inhibition as ERK1/2 is a well-known activator of mTOR, a 
negative regulator of autophagy39. However, we did not test this, rather, we showed 
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that PGE2 stimulation in macrophages downregulates the lipidation of microtubule- 
associated protein 1A/1B-light chain 3 (LC3), an autophagy-related protein, and these 
results were considered a direct measurement of autophagy inhibition. However, 
recently, a role for LC3 in others pathways has been reported including a role in the 
newly identify pathway, LC3-mediated phagocytosis40. Thus, with the set of experiments 
that we performed in chapter 3, we cannot completely conclude that PGE2 specifically 
inhibits autophagy. As a future direction, we should perform autophagy related 
canonical stimulations including rapamycin treatment with and without the presence of 
PGE2, and measure autophagy by visualizing the double membrane vesicle using 
electron microscopy. Using this method, we could conclude whether PGE2 inhibits 
autophagy, specifically. 
5.7 Link between PGE2, autophagy, and the inflammasome. 
 
The inflammasome controls the release of IL-1β, which if dysregulated can lead to a 
decrease in pathogen clearance, or to the development of different IL-1β-driven auto- 
inflammatory syndromes. Here, we show that PGE2 plays a role in exacerbating the 
secretion of IL-1β in macrophages. We have found that this exacerbation is due to 
priming the cells for IL-1β secretion, rather than activating the inflammasome. We 
determined that this was due to elevation of intracellular cAMP, and activation of PKA 
mediated by the receptors EP2 and EP4. However, others have reported that PGE2 
inhibits release of IL-1β when pathogenic signals are activators of the specific NLRP3 
inflammasome41, 42. PGE2-mediated inhibition of the NLRP3 inflammasome was found 
to be mediated by PKA-mediated phosphorylation of the Ser295 residue which inhibits 
its function41. We found that these differences were due to the time of exposure to 
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PGE2. A short exposure (5 minutes in culture) to high levels of PGE2 inhibits the 
NLRP3-mediated secretion of IL-1β by a post-translational modification41. However, 
longer exposures (4 hours in culture) to PGE2 boost the levels of intracellular IL-1β by 
stimulating NFkB and CREB-dependent transcription of the IL-1β gene; thus, amplifying 
amounts of pro-IL-1β for processing after exposure to microbial compounds 4, 23. 
Additionally, although we did not test, another mechanism for PGE2-mediated increase 
of IL-1β can be by the inhibition of autophagy. It has been reported that autophagy 
vesicles can target inflammasome components for degradation to reduce IL-1β 
secretion 43, 44. Thus, PGE2 mediated inhibition of autophagy could lead to a non- 
regulated activation of the inflammasome. To asses this, future experiments should 
focus on the role of PGE2-mediated inhibition of autophagy on IL-1β release. 
5.8 PGE2 mediated inhibition of neutrophil extracellular traps (NETs) 
Neutrophils are the most abundant innate immune effector cell in humans, and their 
antimicrobial responses are essential for combating bacterial infections45. One of the 
major strategies to combat pathogens is the release of NETs, which are decondensed 
chromatin web-like structures loaded with antimicrobial peptides including 
myeloperoxidase (MPO) and neutrophil elastase. NETs can neutralize and kill bacteria, 
fungi, viruses, and parasites45-47. The mechanism of NETs release involves the 
translocation of NE protein into the nucleus by reactive oxygen species (ROS)- 
dependent MPO activation leading to NE-dependent chromatin disruption and histone 
citrullination by protein-arginine deiminase type 4 (PAD4)45. In chapter 4, we tested the 
ability of neutrophils from HSCT patients to secrete NETs by PMA stimulation. We 
detected an impaired ability of neutrophils from HSCT patients to induce NETs. 
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Neutrophils from BMT mice also had an impaired ability to release NETs. We confirmed 
increased levels of PGE2 in our human HSCT subjects (n=12) compared to healthy 
donor volunteers. Increased PGE2 in our patients was independent of age, gender, 
conditioning regimen, and days post-transplant (dpt) (20-806, dpt). Interestingly, 
indomethacin treatment was able to restore normal function for NET release in 
neutrophils coming from HSCT patients. We reported that autocrine stimulation of 
EP2/EP4 in HSCT/BMT neutrophils was responsible for the impairment in NET release. 
Shortly after our publication, another laboratory published similar findings supporting our 
work in a non HSCT context48. The mechanism is still unknown, but we provided 
evidence that might involve the inhibition of autophagy which is a known NET 
regulator49. However, our experimental design was to induce autophagy-mediated 
release of NETs in neutrophils by rapamycin treatments, and measure the impact of 
PGE2 on NET release. We detected decreased release of NETs. However, we did not 
fully measure autophagy in these cells. Thus, as mentioned before, future experiments 
should focus on understanding the possible mechanism of autophagy inhibition by 
PGE2 with a focus on both AMs and neutrophils. Apart from inhibiting autophagy, PGE2 
could be inhibiting NETs by other mechanisms including inhibition of the NADPH 
oxidase. In chapter 4 we reported inhibition of NETs release in neutrophils post-PMA 
stimulation. PMA induction of NETs release has been shown to be dependent on free 
superoxide production with a downstream phosphorylation of the enzymes p38, MAPK 
and ERK. As we, and others, have shown that inhibiting the NADPH oxidase completely 
abolished NETs release, we believe this is a pathway that PGE2 might be interfering 
with as PGE2 has been shown to inhibit NADPH oxidase50. Of note however, PGE2 
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inhibition of NAPH oxidase was shown in AMs and not in neutrophils. To overcome this 
limitation, future experiments should target the PGE2-mediated regulation of NADPH 
oxidase in neutrophils stimulated for NETs release. 
One of the limitations in chapter 4 is that all experiments performed to prove the role of 
PGE2 regulation of NETs were done post-PMA stimulation and not with other stimulants 
including bacterial infections. We can speculate that PGE2 will also inhibit NETs release 
upon bacterial infections as NADPH oxidase plays an essential role in microbial 
clearance. However, NETs release post-bacterial and fungal infections has been shown 
to be dependent on scavenger receptors, in particular Dectin-1. As PGE2 has been 
shown to alter expression of many scavenger receptors, the effects of PGE2 in 
regulation of NETs release upon microbial infection might be different and should be 
addressed. Furthermore, all experiments performed in chapter 4 were performed by 
measuring NETs in an in vitro model; future experiment should focus in measuring NET 
release impairment in vivo using BMT mice. We can do that this by flow cytometry51 
post-S. pneumoniae infection, as we provided evidence that PGE2 decreases S. 
pnuemoniae-mediated NETs release. We can additionally develop BMT chimeras with 
the use of bone marrow from mice lacking essential proteins for NETs release such as 
MPO-/- (MPO deficiency does not block, but delays NETs release52), NE-/- and/or PAD4-/- 
mice. In these mice we can inhibit PGE2 post-S. pneumoniae infection and determine 
whether PGE2 inhibition is unable to improve bacterial clearance. We could also 
consider experiments to measure NETs in histology sections or to treat WT BMT mice 
with DNAse to degrade NETs in vivo and determine outcomes. 
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Even though the mechanism of PGE2 inhibition of NETs release is unknown, its 
implications can provide benefit for combating multiple infections. For example, the 
bacterial pathogens S. aureus46, 53 and P. aeruginosa54, the viral pathogens respiratory 
syncytial virus (RSV) 55 and influenza virus56 as well as the fungal pathogen C. 
albicans57 are all known inducers of NETs and they are all known to cause post- 
transplant infectious complications10, 58-62. So our future experiments should focus on 
understanding the therapeutic benefit that PGE2 inhibition can provide in NETs 
regulation against these microbes in an in vivo model. 
5.9 Polarization of PGE2 in macrophages, and the role of metabolism in this 
process. 
Macrophages are tissue resident immune cells capable of inducing pathogen clearance 
and stimulating adaptive immunity upon encountering foreign molecules. However, 
apart from its many immunological functions, macrophages oversee physiologic 
homeostatic functions including removal of apoptotic cells and iron recycling from 
erythrocytes. Thus, upon pathogen exposure the macrophages adopt a pro- 
inflammatory environment that needs to be tightly regulated. This is known as the M1 
stage. One of the characteristics of the M1 macrophage stage is overexpression of 
inducible nitric oxide synthase (iNOS) as well as pro-inflammatory cytokines including 
IL-1β and TNF-α63. In culture, we can achieve this by stimulating macrophages with a 
pathogen associated molecular patter such as LPS in combination with macrophage 
activating signals such as IFN-γ. In the absence of a pathogenic stimulation, 
macrophages are in an anti-inflammatory stage termed M2. In culture we can achieve 
an M2 stage by stimulating macrophages with IL-4 and IL-13 cytokines. As we noticed 
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that PGE2 stimulation induced high levels of IL-1β, we decided to investigate if it was 
also inducing a M1 stage. To our surprise, when we stimulated macrophages with PGE2 
we couldn’t detect any difference in the M1 marker, iNOS (Figure 5-1 top left). However, 
PGE2 stimulation did have an effect in inducing a higher M2 stage as seen by elevation 
of the M2 marker, Arginase-1, post-M2 stimulation. This phenotype has been reported 
and was determined to be mediated via the cyclic AMP-responsive element binding 
(CREB)-mediated induction of Krupple-like factor 4 (KLF4)64. Even though, PGE2 does 
not induce high levels of iNOS it does induce high levels of IL-1β which is a phenotype 
of M1 polarization. Interestingly when comparing the increased elevation of IL-1β 
transcript levels we find that a single stimulation of PGE2 can raise IL-1β transcript 
levels as strong as dual stimulation with LPS and IFN-y (Figure 5-1, bottom). Moreover, 
together with M1 stimulants, PGE2 can further increase levels of IL-1β. We detected this 
phenotype just with IL-1β and not with IL-6 or TNF-α (data not shown). Our data show 
that PGE2 is not polarizing macrophages into a M1 nor M2 stage, rather it has a direct 
effect in increasing IL-1β transcript levels. One finding that is still not explained is why 
polarization to M2 can limit the ability of PGE2 to induce IL-1β transcript levels (Figure 5- 
1, bottom).  The most likely explanation is that M2 polarization may induce an 
epigenetic change that limits access of transcription factors to the IL-1β promoter. This 
is another area for future investigation. 
Others have reported macrophage polarization stages with characteristic of both M1 
and M2. These macrophages are termed regulatory macrophages and it can be 
achieved by prostaglandin stimulation as well as by stimulation with apoptotic bodies 
and IL-1065. However, the direct effect on IL-1β but no other pro-inflammatory cytokines, 
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makes us believe that PGE2 might not be inducing a regulatory stage. To clearly study 
the effects of PGE2 in macrophage polarization we might want to study its effects in 
macrophage metabolism rather than measuring canonical markers of macrophage 
polarization. This is because macrophage polarization and metabolism are tightly 
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Figure 5-1 PGE2 increases IL-1β expression without inducing a canonical M1 polarization stage. BMDMs were treated or not with 
LPS (100ng/ml) and IFN-γ (50ng/ml) to induce M1 stage or treated with IL-14 (10ng/ml) and IL-13 (10ng/ml) to induce M2 stage together 
or not with PGE2 (1μM). All stimulations were performed for 6 hours and iNOS (top left), Arginase-1 (top right), and IL-1β (bottom) gene 
expression was assesses by RTq-PCR. One-way ANOVA with Bonferroni’s post-test. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. 
* * * * 
N S 
* 
* * 
* * * * 
R
 e
 l
a
 t
 iv
 e
 
E
 x
 p
 r
 e
 s
 s
 i
o
 n
 
R
 e
 l
a
 t
 i
v
 e
 
E
 x
 p
 r
 e
 s
 s
 i
o
 n
 
128  
associated. M1 macrophages increase glucose consumption and lactate release and 
decrease oxygen consumption rate whereas M2 macrophages mainly employ oxidative 
glucose metabolism pathways66. Thus, to understand the role of PGE2 in polarization, 
future experiments should focus on the effect of PGE2 in macrophage metabolism. 
5.10 Cyclooxygenase (COX) inhibitors as a therapeutic strategy 
 
In this dissertation, I successfully used a non-selective COX inhibitor, indomethacin, to 
restore immunity to bacterial pathogens in BMT mice and HSCT neutrophils. However, 
indomethacin, together with other non-steroidal inflammatory drugs (NSAIDs), 
especially selective COX-2 inhibitors, have been shown to be highly toxic leading to 
serious gastrointestinal and cardiovascular injury67, 68. Thus, therapeutic strategies 
should focus not just on decreasing PGE2 levels but also on reducing toxicity. To 
overcome this, we should use more selective inhibitors of the PGE2 signaling pathway. 
In mice, researchers have shown improved outcome in disease models with selective 
antagonists for EP2 and EP423. Additionally, we could consider specific inhibitors of 
microsomal PGE synthase-1 (mPGES1), the enzyme downstream of COX and 
responsible for PGE2 synthesis, which has been shown not to induce cardiovascular 
injury. Thus, future experiments should focus on replicating our findings with the use of 
selective antagonists for EP2 and EP4 as well as inhibitors of mPGES1. Additionally, 
we can opt for treating our BMT mice with indomethacin loaded nanoparticles69, which 
will be ingested by phagocytic cells leading to decreased toxicity, prior to bacterial 
challenge. This therapeutic strategy has been tried as an inhaled therapy, with other 
drugs, to treat pulmonary bacterial infections70. 
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HSCT patients are routinely prescribed immunosuppressive drugs to treat or prevent 
GVHD (allogeneic transplant) and or other drugs including antibiotics, antifungal or 
antiviral drugs to prevent infections9, 71-73. Our findings showing a role for PGE2 
inhibition in improving antimicrobial response is not intended to be used as a single 
treatment post-HSCT, but rather, to be used in combination with other drugs that HSCT 
patients may also be prescribed. Thus, our findings need to first be tested in Phase 1 
clinical trials to help understand the right dose and frequency with which the drug needs 
to be given in order to reduce PGE2 levels systemically or locally in the lung and to 
detect whether there is a significant decrease in frequency of infections compared to 
placebo control. 
In this dissertation we focus particularly on HSCT patients, who are known to have 
exacerbated levels of PGE274. However, our findings can be relevant also in a non- 
HSCT context as naturally secreted PGE2 can be inhibited to improve bacterial 
clearance even in cells from control subjects50, 75-80. Additionally, a research article, 
shortly published after our findings in chapter 3, showed how endogenous PGE2 is 
necessary for IL-1β induction81. In that article, inhibition of PGE2 by indomethacin led to 
decreased LPS-induced IL-1β in macrophages. Thus, our findings related to inhibition of 
PGE2 to reduce IL-1β-ALI should be tested in a non-HSCT setting as well and may be 
able to improve outcomes for ALI caused by many stimuli. 
5.11 Summary 
 
My doctoral dissertation research work aims to identify cell signaling pathways, 
mediators, and/or strategies to combat respiratory bacterial infections in HSCT patients. 
These patients have high levels of PGE2 in the serum and BALF. PGE2 is a known 
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immune suppressor against multiple pathogens. Here, I decided to focus on the 
implication of high levels of PGE2 in regulating immunity to bacterial infections. Two of 
my major research projects are well described in chapter 3 and 4 of this dissertation. In 
chapter 3, I identified that high levels of PGE2 induces exacerbated levels of IL-1β in 
BMT mice leading to severe ALI post-P. aeruginosa infection. This is dependent on 
adenyl cyclase (AC) activation by EP2 and/or EP4 receptor stimulation which leads to 
activation of the transcription factor CREB. Furthermore, reducing levels of PGE2 with 
indomethacin treatments was able to decrease IL-1β levels, improve bacterial killing, 
and reducing ALI in BMT mice post-P. aeruginosa infection. In chapter 4, together with 
a fellow graduate student at the time, we showed how PGE2 production impaired NET 
release in murine and human neutrophils. Furthermore, indomethacin treatments were 
able to restore NET release. Our findings suggest new therapeutic strategies aimed at 
blocking PGE2 production or signaling may have positive impacts against bacterial 
infections in HSCT subjects. 
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Chapter 6. 
 
Influenza-induced immune suppression to Staphylococcus aureus is 
mediated by TLR9 
6.1 Abstract 
 
Bacterial infections, particularly with methicillin-resistant Staphylococcus aureus 
(MRSA), increase mortality following influenza infection, but the mechanisms remain 
unclear. Expression of TLR9, a microbial DNA sensor, is increased in murine lung 
immune cells including macrophages, dendritic cells, and CD8+ T cells, post-influenza 
infection. TLR9-/- mice did not show differences in handling single viral nor bacterial 
infection. Surprisingly however, TLR9-/- mice have improved survival and bacterial 
clearance in the lung post-influenza and MRSA coinfection, with no difference in viral 
load. Improved bacterial clearance post-coinfection was specific for MRSA, as there 
was no difference in the clearance of Streptococcus pneumoniae. Additionally, inhibition 
of TLR9 in vivo reduces lung bacterial burden post-MRSA coinfection. IFN-γ does not 
play a role in MRSA clearance. Rather, TLR9-/- macrophages exhibit improved bacterial 
clearance, phagocytosis, and inducible nitric oxide synthase expression (iNOS) post- 
influenza infection. Thus, TLR9 inhibition improves the clearance of MRSA coinfection 
potentially by increasing macrophage antimicrobial function. 
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6.2 Background 
 
Influenza viruses are single-stranded RNA viruses with a segmented genome (8 
RNA molecules, encoding 10 proteins) capable of mutating their antigens to evade host 
immunity and causing seasonal outbreaks, leading to over a half million deaths per 
year, worldwide (World Health Organization, 2016)1. Their nature allows them to 
overcome traditional vaccine strategies such as inoculation with attenuated viruses, as 
this will not confer protection to antigenic alterations 2. There are three types of 
influenza viruses that can infect humans (A, B, and C). Influenza A virus (IAV) is the 
most severe and the main cause of seasonal outbreaks. IAV infections can be 
complicated by bacterial pathogens including Staphylococcus aureus, and 
Streptococcus pneumoniae leading to increased morbidity and mortality 3. 
Retrospective studies have shown that 95% of the deaths caused by the 1918 influenza 
pandemic (Spanish Flu) were complicated by bacterial superinfections 3, 4. Furthermore, 
whole-blood transcriptome analysis of over 225 influenza-infected patients showed a 
shift and enrichment in gene signatures from viral response to bacterial response in 
critically ill patients 5. Thus, to decrease morbidity and mortality of IAV infections we 
need a better understanding of how to treat secondary bacterial infections. Past studies 
have found that IAV infections can lead to secondary bacterial infections in different 
ways including increasing the attachment sites for bacteria, reducing responsiveness of 
immune cells, and reducing efficiency of antibiotics 6-8. Yet, the mechanism underlying 
influenza-induced mortality is poorly understood and we are still lacking better 
therapeutic strategies to improve outcomes for influenza-infected individuals. 
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Toll-like receptors (TLRs) are germline encoded pathogen recognition receptors 
capable of initiating innate immune responses, and regulating adaptive immunity to both 
viral and bacterial pathogens9. They are primarily expressed in immune cells, and are 
membrane bound and distributed in the extracellular membrane and endosomes 
making them able to recognize extracellular and intracellular microbial components 10. 
Manipulation of TLRs has shown great potential in combating bacterial infections. For 
example, agonistic stimulation of TLR4, a lipopolysaccharide (LPS) receptor, has been 
shown to improve bacterial clearance in Pseudomonas aeruginosa infected mice 11. IAV 
has been shown to alter the expression of TLRs including downregulation of TLR2, a 
bacterial lipopeptide sensor, in human monocytes and dendritic cells 12. TLR2 agonist 
stimulation was shown to have therapeutic potential when reported to improve survival 
as well as bacterial and viral clearance in a mouse model of viral-bacterial coinfection 13. 
Little is known about the role of other TLRs that are altered in IAV infections and their 
implications in secondary bacterial infections. 
 
 
IAV infection was shown to increase the expression of TLR9 in human monocytes and 
dendritic cells 12. TLR9 is an endosomal receptor that recognizes unmethylated cytosine 
and guanine (CpG) motifs which are rich in viral and bacterial DNA and mitochondrial 
DNA (mDNA)14, 15. Here, we aim to study the role of TLR9 in IAV associated bacterial 
secondary infections, particularly with the bacterial pathogen methicillin-resistant 
Staphylococcus aureus (MRSA). Studying MRSA secondary infections is of high 
importance as in recent pandemics it has been the main cause of secondary pneumonia 
in IAV infected individuals 16. Additionally, MRSA is the leading cause of bacterial 
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infections in humans worldwide, and infections are difficult to treat as MRSA is resistant 
to all known β-lactam antibiotics 17. 
 
With the use of a mouse-adapted IAV strain, A/Puerto Rico/8/1934 (PR8), we found that 
TLR9 expression is elevated in lung macrophages, dendritic cells, and CD8 T cells from 
PR8 infected mice. TLR9-/- mice infected with PR8 or MRSA did not differ from wildtype 
(WT) mice, but they experience improved survival post PR8-MRSA coinfection. Even 
though TLR9-/- mice didn’t have a difference in viral titers or acute lung injury in the 
measured time points, they did experience improved bacterial clearance post 
coinfection. The resistance to coinfection found in TLR9-/- mice was specific to the 
synergism between PR8 and MRSA, as TLR9-/- mice did differ in bacterial clearance 
when challenged with PR8 and Streptococcus pneumoniae. Interestingly, TLR9-/- 
macrophages post-PR8 infection experience increased bacterial phagocytosis and 
intracellular killing. Additionally, TLR9-/- macrophages have increased inducible nitric 
oxide synthase (iNOS) expression post-PR8 compared to WT. Our findings show a 
previously unrecognized role of TLR9 in influenza infection, in which TLR9 inhibition can 
serve to combat secondary MRSA superinfections. 
6.3 Results 
 
IAV increases expression of TLR9 in macrophages. Changes in expression of 
different toll-like receptors (TLRs) (TLR2, TLR3, TLR4, TLR7, TLR8, and TLR9) have 
been reported before in human monocytes and dendritic cells from seasonal influenza 
infected patients 12. In our murine experiments, we noticed that just TLR9 gene 
expression is increased in lung immune cells 5 days post-PR8 infection (Fig.6-1A). 
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Protein expression was also increased in these cells post-PR8 infection as measured by 
TLR9 immunoblotting (Fig.6-1B). To understand which cells were upregulating TLR9, 
we used flow cytometry to characterize the major immune cells in the lung 
compartment. We noticed that CD8 T cells, macrophages (interstitial and alveolar), and 
dendritic cells were the main cells expressing higher TLR9 expression post-PR8 (Fig.6- 
1C). We did not notice changes in CD4 T cells, NK cells, B cells, and neutrophils (Fig.6- 
1C). Adherence selection of lung macrophages, after lung collagenase digestion, 
allowed us to detect gene expression changes in multiple TLRs in lung 
monocytes/macrophages after influenza infection. We noticed that apart from TLR9 
being increased, TLR3 and TLR2 were also altered with increased and decreased 
expression, respectively (Fig.6-1D). These later observations were also seen in human 
monocytes of influenza-infected individuals 12. Interestingly, direct infection of isolated 
alveolar macrophages with PR8 shows an increase in TLR9 and TLR3, with no changes 
in TLR2, 4, and 7 (Fig.6-1E). We also detected TLR9 increased 24 hours post-PR8 
infection in cultured bone marrow derived macrophages (BMDMs) (Fig.6-2A). To our 
knowledge, we are the first to report that direct infection of macrophages with IAV can 
increase TLR9 expression. This increase was likely independent of IAV recognition by 
TLR7, or by IAV-induced release of CpG rich mDNA as TLR7, and TLR9 agonist 
stimulation lead to downregulation of TLR7 and TLR9 gene expression (Fig.6-2B). 
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Figure 6-1: TLR9 overexpression in lung immune cells post-IAV infection. (A) Relative gene expression of TLRs 
by RTqPCR and (B) western blotting of TLR9 and β-actin. RNA and protein were isolated from lung immune cells 
post-collagenase digestion in mice infected with 100 PFUs of H1N1 (PR8) for 5 days or placebo (PBS). β-actin was 
used to normalize RNA in samples. (C) Frequency of TLR9+ cells measured by flow cytometry in lung immune cells 
post-collagenase digestion. Gating was as follows: CD4+ T cells (CD45+,CD90.2+, CD3+, CD4+), CD8+ T cells 
(CD45+,CD90.2+, CD3+, CD4-, CD8+), natural killer cells (CD45+,CD90.2+, NKp46+), B cells (CD45+,CD90.2-, CD19+), 
neutrophils (CD45+, CD11b+, LY6G+), interstitial macrophages (CD45+, CD64+, CD11b+, F4/80+), alveolar 
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macrophages (CD45+, CD64+, CD11C+, Siglec F+) and dendritic cells (CD45+, CD64-, CD11c+, MCHIIhigh). (D) 
Relative expression of TLRs after lung macrophage isolation by adherence selection from PBS or IAV-infected mice. 
(E) Relative expression of TLRs in alveolar macrophages infected or not ex-vivo with H1N1 (MOI:0.01) for 24 hours. 
Statistics are student T test between comparative groups. *P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. 
 
 
 
TLR9-/- mice are resistant to IAV and MRSA coinfection. Secondary bacterial 
infections in influenza infected individuals are a main cause of mortality and morbidity 18. 
To study this synergistic effect between the virus and the bacteria, we used a well- 
known IAV-MRSA coinfection model consisting of an initial viral infection followed by a 
secondary bacterial infection (Fig.6-3A); where we can detect susceptibility to MRSA 
infection as early as 5 days post-PR8 infection (Fig.6-4). We observed a dramatic 
survival difference between TLR9-/- and WT mice, where 70% of TLR9-/- mice survived 
the secondary bacterial infection compared to 10% of WT mice (Fig.6-3B). There were 
no significant differences in weight changes between TLR9-/- and WT mice noted (Fig.6- 
3C). 
Figure 6-2: TLR7 or TLR9 agonist stimulation does not increase expression of TLR9. (A) BMDMs infected or 
not with IAV at a MOI of 0.01 for 48 hours. (B) BMDMs were treated with the TLR9 agonist, ODN 2395, or with the 
TLR7 agonist, imiquimod (R837), for 24 hours at a concentration of 1μM or 1μg/ml, respectively. RNA was isolated 
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and TLR9 transcript expression was measured by RTqPCR. Statistics are student T test between comparative 
groups;***P˂0.001. 
 
 
Figure 6-3: TLR9-/- mice are resistant to secondary bacterial infection. (A) Sketch of infection model where 
Balb/c and TLR9-/- mice are infected with 100 PFUs of H1N1 5 days prior to infection with 7x107 CFUs of MRSA 
(US300). Mice are monitored daily to check for survival. (B) Survival assay of Balb/c (n=9) and TLR9-/- (n=9) mice 
following coinfection. (C) Weight changes (left) and initial weight (right) of all mice used in survival assay. Statistics 
for weight changes and initial weight were student T test, non-significant (ns). Statistics in survival assay were done 
with the Log-rank (Mantel-Cox), *P˂0.05. 
 
TLR9-/- and WT mice show similar susceptibility to MRSA infection alone. 
Currently, there are conflicting results regarding the role of TLR9 in single MRSA 
infection 19, 20. To understand if TLR9-/- mice are susceptible to a single MRSA infection 
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independent of the initial IAV infection, we performed a survival assay post-MRSA 
infection. We did not detect a difference in survival between TLR9-/- and WT mice (Fig.6- 
5A). Interestingly, weight recovery during the infection was slower in TLR9-/- mice, but 
mice were able to recover the lost weight during the survival monitoring (Fig.6-5B). We 
detected reduced immune cell infiltration in the alveolar compartment post-MRSA 
infection in TLR9-/- mice (Fig.6-5C). However, this did not affect bacterial clearance or 
lung injury which was reduced significantly 48 hours post-infection (Fig.6-5D-E). 
Previous work has shown that TLR9-/- mice have reduced TNF-α in the BALF post- 
MRSA 20. We detected lower amounts of TNF-α, IL-6, and IL-10 in the BALF of MRSA- 
infected TLR9-/- mice (Fig.6-5F). Yet, lower amounts of these cytokines did not have a 
negative effect on bacterial clearance, lung injury, or survival. Reduced immune cell 
infiltration and cytokine profile might be explained by lower NF-κB activation post-MRSA 
infection as TLR9 is a sensor of bacterial DNA 21. 
 
TLR9
-/- 
mice experience improved MRSA clearance post-coinfection. We were able 
to detect better bacterial clearance in the IAV-infected TLR9-/- mice 24 hours post-MRSA 
infection, but no difference in tissue injury or viral load (Fig.6-6A-C). Synthetic 
oligonucleotides (ODNs) are single-stranded synthetic DNA molecules containing 
unmethylated CpG which can be modified to work as either agonists or antagonists of 
TLR9. To test whether TLR9 signaling inhibition during viral-bacterial coinfection can 
lead to improved bacterial clearance, we treated WT mice with 3 equal doses of a TLR9 
antagonist, ODN 2088 (Fig.6-6D). As expected, mice that were treated with TLR9 
antagonist experience improved bacterial clearance compared to mice treated with 
149  
control ODN (Fig.6-6D). These findings suggest that TLR9 blockade during IAV infection 
can improve immunity to a secondary MRSA infection. 
 
 
Figure 6-4: Reduced MRSA clearance, and exacerbated lung tissue injury in the lung post-IAV infection. 
Bacterial load measurement in the whole lung of mice infected, or not, with (a) 10 PFUs or (b) 100 PFUs and co- 
infected with MRSA 5, 7 or 10 days post-H1N1 infection. Albumin measurements from the BALF of (c) 10 PFUs or (d) 
100PFUs IAV-infected or not mice for 5, 7 and 10 days and co-infected with MRSA for 24 hours. Relative expression 
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of M1 viral gene in lungs of mice infected with 10 PFUs (E) or 100 PFUs (F) of IAV, samples were taken on days 3, 5, 
7, and 10 post-infection. Statistics are student T test between comparative groups. *P˂0.05 ,**P˂0.01, ***P˂0.001, 
****P˂0.0001; # two mice died in this group before bacterial load measurement. 0 dpi mice were infected with 
placebo, PBS, 5 days before MRSA coinfection. 
 
 
 
Higher bacterial clearance in TLR9
-/- 
mice post-coinfection is independent of 
exacerbated levels of IFN-γ. To understand whether TLR9-/- mice are clearing the 
bacteria better post coinfection due to differences in their cytokine profile, we measured 
the levels of different pro and anti-inflammatory cytokines. We detected reduced 
amounts of TNF-α, IL-1β, IL-6, and IL-17, but increased levels of IFN-γ (Fig.6-7A). High 
levels of IFN-γ have been shown to improve MRSA clearance due to full activation of 
macrophages 22. Together with this, we detected higher numbers of TH1 
(CD45+,CD90.2+,CD4+,IFN-γ+), CD8 T (CD45+,CD90.2+,CD4-,CD8+,IFN-γ+), and NK 
(CD45+,CD90.2+,NKP46+,IFN-γ+) cells, but no difference in other immune cells including 
B cells (CD45+,CD90.2-,CD19+), and CD4 T (CD45+,CD90.2+,CD4+) cells (Fig.6-7C). To 
test whether high levels of IFN-γ in the bronchoalveolar lavage fluid (BALF) were 
responsible for the improved bacterial clearance in TLR9-/- mice, we neutralized IFN-γ 
during IAV-MRSA coinfection. To our surprise, there was no difference between isotype- 
treated and IFN-γ-neutralized mice (Fig.6-7C-D). Thus, improved bacterial clearance in 
TLR9-/- mice is independent of high levels of IFN-γ. 
 
IFN-γ inhibits Streptococcus pnuemoniae (SPS3) clearance but has no effect on 
MRSA. IFN-γ has been shown to play a negative role in SPS3 clearance post-IAV 
infection by decreasing the expression of macrophage receptor with collagenous 
structure (MARCO) 23. Just like MRSA, SPS3 is a Gram-positive bacterial pathogen that 
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Figure 6-5: TLR9-/- mice experience no difference in MRSA clearance. (A) Survival assay of BALB/c (n=8) and 
TLR9-/- (n=5) mice infected with 1.3x108 CFUs of MRSA (US300). (B) Weight changes (left) and initial body weight 
(right) of mice used in survival assay. (C) Total amount of cells (left) and percentage of leukocytes (right) in the 
alveolar compartment of BALB/c and TLR9-/- mice quantified using a hemocytometer and differential staining; 
samples were taken by BAL 24 hours post-MRSA (7x107 CFUs) infection. (D) Lung bacterial burden & (E) Albumin 
measurements in the BALF 24 and 48 hours post-MRSA (7x107 CFUs) infection in BALB/c and TLR9-/- mice. (F) 
Cytokine levels in the BALF of BALB/c and TLR9-/- mice infected with MRSA (7x107 CFUs) for 24 hours. Cytokines 
were measured by ELISA. (B), (C) & (F) Statistics are student T test between comparative groups; ns=non- 
significant, **P˂0.01, ***P˂0.001. (D) and (E) statistics were obtained by one-way analysis of variance with 
Bonferroni’s posttest. ****P˂0.0001. 
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is a high threat to influenza-infected individuals 24, 25. When examining outcomes with 
IAV and SPS3 more fully, we found that TLR9-/- mice have no difference in SPS3 
clearance with or without an initial influenza infection (Fig.6-8A). Thus, improved 
bacterial clearance in TLR9-/- mice post-IAV seems to be specific to MRSA. INF-γ levels 
in the BALF of TLR9-/- mice after IAV-SPS3 infection were not significantly higher than in 
WT mice (Fig.6-8B). To test whether high levels of IFN-γ have a different effect on 
MRSA and SPS3 clearance, we gave recombinant IFN-γ intratracheally before the 
bacterial infection and measured lung bacterial burden 24 hours after infection. As 
expected, we were able to detect immunosuppression to SPS3, but IFN-γ had no effect 
on the clearance of MRSA. The negative role of IFN-γ in the pathogenesis of SPS3 
post-IAV was attributed to decreased expression of MARCO. We detected lower 
expression of MARCO with higher expression of SRAI/II in macrophages from mice 
infected with IAV (Fig.6-9). Previous work reported that decreased expression of 
MARCO but increased expression of SRAI/II can improve phagocytosis of MRSA 26. To 
test if IFN-γ has different effects on phagocytosis of MRSA and SPS3, we treated 
BMDMs with IFN-γ and assessed their phagocytosis capability. We found that IFN-γ 
improves MRSA uptake, but decreases SPS3 uptake (Fig.6-10B). This effect was not 
seen in opsonized bacteria, suggesting the effect is specific to alteration in scavenger 
receptors (Fig.6-10C). Thus, even though IFN-γ improves MRSA uptake, it doesn’t 
improves its clearance (Fig.6-10D). 
 
 
TLR9
-/- 
lung macrophages have increased phagocytosis, bacterial killing, and 
iNOS expression post-IAV infection. To determine if IAV was inducing changes to 
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Figure 6-6: TLR9-/- mice experience improved bacterial clearance post-IAV and MRSA coinfection. (A) Bacterial 
burden in lungs & (B) Albumin levels in BALF from BALB/c and TLR9-/- mice that were infected with IAV (100 PFUs, 
H1N1) or treated with placebo, PBS, 5 days prior to MRSA (7x107 CFUs) infection; samples were harvested 24 hours 
post-MRSA infection. (C) Quantification of influenza titers in whole lung of BALB/c and TLR9-/- mice infected with 
influenza (100 PFUs, H1N1) 5 days prior to MRSA (7x107 CFUs) infection or PBS treatment. (D) Lung bacterial 
burden from BALB/c mice treated with three doses (50μg) of control ODN or TLR9 inhibitor (ODN 2088) and infected 
or not with IAV (100 PFUs, H1N1) 5 days prior to MRSA (7x107 CFUs) infection. (A-C) Statistics were obtained by 
one-way analysis of variance with Bonferroni’s posttest; ns=non-significant, *P<0.05, **P˂0.01, ***P˂0.001. (D) 
Statistics are student T test between comparative groups; ns=non-significant, **P˂0.01, ***P˂0.001. 
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TLR9-/- mice that were leading to resistance to a MRSA infection, we measured the 
cytokine profile in the BALF, and lung immune cell profile in TLR9-/- mice post-single IAV 
infection. There was no difference in cytokines or lung immune cells 5 days post-IAV 
infection (Fig.6-11A and Fig.6-12). Interestingly, macrophages isolated from IAV-infected 
TLR9-/- mice have increased intracellular MRSA clearance and phagocytosis (Fig.6-11B- 
C). Additionally, TLR9-/- lung macrophages have higher levels of iNOS post-IAV 
compared to WT (Fig.6-11D). Nitric oxide production has been shown to be crucial in 
clearing MRSA infection 27. To test whether TLR9 expression might suppress iNOS 
increase, we infected BMDMs from WT and TLR9-/- mice and measured iNOS 
expression. TLR9-/- macrophages have higher expression of iNOS post-IAV infection 
suggesting that TLR9 is a negative regulator of iNOS expression post-IAV infection. 
 
 
6.4 Discussion 
 
Lower respiratory infections are the fourth leading cause of death with 3 million 
deaths each year worldwide (WHO, 2018). The influenza virus infects the upper and 
lower respiratory tract and is successful at infecting 3-5 million individuals each year, 
taking the life of nearly a half million of these individuals 1. Severe illness and death in 
influenza infections are seen mostly in high risk subjects, the very young and elderly. 
However, recent influenza outbreaks have taken the life of young healthy citizens 
creating public health concerns. Secondary bacterial superinfections are responsible for 
the high morbidity and mortality in influenza-infected patients 18. Even with proper care 
including influenza vaccines, hygiene, and antibiotics, influenza-associated secondary 
bacterial infections are a burden to public health 28. Additionally, the over-use of 
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Figure 6-7: Higher bacterial clearance in TLR9-/- mice post-IAV and MRSA coinfection is independent of 
exacerbated levels of IFN-γ. (A) Cytokine measurement in BALF from BALB/c and TLR9-/- mice that were infected 
with IAV (100 PFUs, H1N1) 5 days prior to MRSA (7x107 CFUs) infection. (B) Absolute number of lung immune cells 
post-lung collagenase digestion in BALB/c and TLR9-/- mice that were infected with IAV (100 PFUs, H1N1) 5 days 
prior to MRSA (7x107 CFUs) infection. Cells were quantified by flow cytometry; gating was as follow: B cells 
(CD45+CD90.2-CD19+); CD4+ T cells (CD45+CD90.2+CD4+); TH1 (CD45+CD90.2+CD4+,IFN-γ+); CD8+ T cells 
(CD45+CD90.2+CD4-,CD8+,IFN-γ+); NK cells (CD45+CD90.2+NKP46+,IFN-γ+). (C) Lung bacterial burden and (D) IFN- 
γ levels in BALB/c and TLR9-/- mice that were treated with 200μg of IFN-γ neutralizing antibody or isotype control and 
infected with IAV (100 PFUs, H1N1) 5 days prior to MRSA (7x107 CFUs) infection. (A-B) Statistics are student T test 
between comparative groups; ns=non-significant, *P˂0.05, **P˂0.01, ***P˂0.001, ****P˂0.0001. (C-D) Statistics were 
obtained by one-way analysis of variance with Bonferroni’s posttest; ns=non-significant, *P<0.05, **P˂0.01. 
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antibiotics has led to the selection of multidrug resistant bacterial pathogens making it 
harder to reduce the severity of bacterial infections 17. Thus, we are currently in need of 
better therapeutic strategies against viral-bacterial co-infections that can improve public 
health. Influenza infections have been shown to alter the expression of TLRs in immune 
cells 12. Manipulation of TLRs, in particular TLR2, has been shown to improve survival, 
and microbial clearance in mice coinfected with influenza and bacterial pathogens 13. 
However, little is known about the potential roles that other TLRs can have in controlling 
viral-bacterial coinfections. 
 
 
TLR9 is an intracellular receptor that recognizes unmethylated CpG motifs which are 
rich in microbial DNA 14. TLR9 expression was reported to be elevated in monocytes 
and dendritic cells from influenza-infected patients compared to healthy individuals 12. 
Here, we noted that IAV infection similarly increases TLR9 expression in murine 
immune cells from mice infected with a mouse-adapted IAV strain (PR8) (Fig.6-1A-D). 
This increase can also be achieved in cultured alveolar macrophages (Fig.6-1E) and 
BMDMs (Supplemental Fig.6-1A) infected in vitro. We tested whether stimulation of 
TLR7, the innate influenza sensor, could lead to increased expression of TLR9 as it is 
known that NF-κB activation by TLRs can induce TLR expression 29. However, we did 
not detect upregulation of TLR9 after TLR7 stimulation (Fig.6-2A). Influenza infections 
can lead to mitochondrial membrane permeabilization and release of mitochondrial 
components30. Release of mDNA can also lead to activation of TLR9 due to mDNA’s 
high concentration of unmethylated CpG 15, 21. However, we found that CpG 
oligonucleotide stimulation of TLR9 did not increase TLR9 expression in our 
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experiments (Fig.6-2B). Thus, there’s still no clear evidence for how the IAV virus leads 
to the increased TLR9 expression noted in mice and humans. 
 
Figure 6-8: TLR9-/- mice have no difference in clearance of Streptococcus pnuemoniae and have no difference 
in IFN-γ. (A) Lung bacterial burden and (B) cytokine levels in BALB/c and TLR9-/- mice infected with IAV (100 PFUs, 
H1N1), or treated with PBS, 5 days prior to Streptococcus pneumoniae (SPS3) (3x105 CFUs) infection; samples were 
taken 24 hours post SPS3 infection. Statistics are student T test between comparative groups. Non-significant (ns), 
*P˂0.05 ,**P˂0.01, ***P˂0.001, ****P˂0.0001. 
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Mice lacking TLR9 (TLR9-/- mice) did not differ in viral response against IAV compared 
to WT as there was no difference in measured viral titers, cytokine profiles, tissue injury, 
or immune cell infiltration (Fig.6-6C, Fig.6-8A, and Fig.6-12). However, TLR9-/- mice 
were resistant to an IAV-MRSA coinfection with improved bacterial clearance (Fig.6-3 
and Fig.6-6A). Interestingly, TLR9-/- mice did not clear the virus differently and there was 
no difference in acute tissue injury (ATI) post coinfection (Fig.6-6B-C). The improved 
clearance of MRSA in TLR9-/- mice was not due to a preexistent resistance to the 
bacteria either as there was no difference in single MRSA infection (Fig.6-5) between 
WT and TLR9-/- mice. Previous reports focused on the role of TLR9 in single MRSA 
infection have shown conflicting results. MRSA was shown to induce a type I interferon 
response dependent on TLR9, and TLR9-/- mice were reported to have lower TNF-α and 
improved bacterial clearance19. In contrast, TLR9-/- mice were reported to have 
decreased MRSA clearance despite the lower amount of TNF-α 20. Similar to the 
previous findings, we noticed a decrease in cytokine secretion in TLR9-/- mice, 
specifically TNF-α was lower (Fig.6-5F); however, TLR9-/- mice did not differ from WT in 
bacterial clearance, survival and ATI despite lower lung immune cell infiltration and 
cytokine release (Fig.6-5). Thus, TLR9 seems to play a unique role in resistance to 
MRSA only in the context of secondary bacterial infection post-IAV. 
 
 
TLR9-/- mice have increased IFN-γ in the BALF together with higher numbers of IFN-γ 
producing cells (TH1, CD8 T cells, and NK cells) in the lung post coinfection (Fig.6-7A- 
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Figure 6-9: IAV infection alters scavenger receptor levels. MARCO and SRA I/II relative expression in 
macrophages from BALB/c mice 5 days post-IAV infection at a 100 PFUs. Statistics are student T test 
between comparative groups; *P˂0.05, ****P˂0.0001 
 
B). This increase in IFN-γ provided a potential explanation for the improved bacterial 
clearance in TLR9-/- mice as IFN-γ has been shown to increase clearance of MRSA 22. 
However, in our studies, INF-γ neutralization (confirmed by ELISA (Fig 6-7D) and 
bioassay (data not shown) was not able to decrease clearance of MRSA in TLR9-/- mice 
(Fig.6-7C). Therefore, the enhanced clearance on MRSA is independent of IFN-γ. As 
this cytokine was shown before to decrease clearance of SPS3 post-IAV 23, we 
investigated whether IFN-γ can have a different effect between MRSA and SPS3. 
Treating mice with IFN-γ and then challenging with MRSA or SPS3 showed that IFN-γ 
can decrease clearance of SPS3 but has no effect on MRSA clearance (Fig.6-10A). In 
culture, IFN-γ can decrease phagocytosis of SPS3 whereas this cytokine actually 
improves the phagocytosis of MRSA (Fig.6-10B). However, despite improved 
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phagocytosis, macrophages can’t effectively kill intracellular MRSA (Fig.6-10D). 
Previous findings have shown that S. aureus is able to evade immunity and survive 
inside cells including phagocytic cells 17. This is consistent with our data showing that 
IFN-γ can improve phagocytosis of MRSA without improving its clearance. 
 
 
Figure 6-10: Administration of IFN-γ inhibits S. pnuemoniae clearance but has no effect in MRSA clearance, 
in vivo. (A) Lung bacterial burden of BALB/c mice that were treated or not with recombinant IFN-γ (2μg) prior to 
infection with MRSA (7x107 CFUs) or SPS3 (3x105 CFUs) for 24 hours. (B) In vitro phagocytosis assay where 
BMDMs were treated with IFN-γ (10ng/ml), or mock, for 24 hours prior to treatment with heat inactivated and FITC- 
labeled MRSA and/or SPS3. (C) In vitro phagocytosis assay and (D) in vitro bacterial survival assay where BMDMs 
were treated with IFN-γ (20ng/ml), or mock, for 24 hours prior to challenge with opsonized MRSA and/or SPS3. 
Statistics are student T test between comparative groups. Non-significant (ns), *P˂0.05 ,**P˂0.01, ***P˂0.001. 
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Figure 6-11: TLR9-/- lung macrophages have increased phagocytosis, bacterial killing, and iNOS expression 
post-IAV infection. (A) Cytokine measurement in BALF from BALB/c and TLR9-/- mice that were infected with IAV 
(100 PFUs, H1N1) for 5 days. (B) Ex vivo MRSA phagocytosis and (C) Intracellular survival assay using adherence 
selected lung macrophages from BALB/c and TLR9-/- mice that were infected with IAV (100 PFUs H1N1) for 5 days or 
treated with PBS. (D) Quantitative reverse transcriptase-PCR measurement of relative gene expression of iNOS from 
adherence selected lung macrophages from BALB/c and TLR9-/- mice that were infected with IAV for 5 days or 
treated with PBS; RNA samples were normalized to their β-actin levels. (B-C) Statistics were obtained by one-way 
analysis of variance with Bonferroni’s posttest; ns=non-significant, *P<0.05. (A and D) Statistics are student T test 
between comparative groups. Non-significant (ns), ***P˂0.001 
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Shortly after infection, MRSA is engulfed by phagocytes 31. Macrophages, especially M1 
(antimicrobial) polarized macrophages, play an essential role in the clearance of MRSA 
32. So, we tested the ability of macrophages from TLR9-/- mice to clear MRSA in culture. 
 
TLR9-/- macrophages isolated from uninfected mice had no difference in phagocytosis 
or intracellular bacterial clearance compared to WT. However, macrophages from PR8- 
infected TLR9-/- mice are capable of improving bacterial clearance and killing (Fig.6- 
11B-C). Interestingly, TLR9-/- macrophages from infected mice have higher expression 
of iNOS (Fig.6-11D). Mice lacking iNOS expression are deficient in clearance of MRSA 
and more than 50% of mice will not survive a MRSA infection past 24 hours27. Thus, 
the induction of iNOS is the most likely explanation for why TLR9-/- macrophages are 
more effective at clearing MRSA post-IAV infection. 
 
 
In conclusion, our findings provide evidence that TLR9 plays a negative role in IAV- 
associated secondary MRSA infections. Blocking of TLR9 post-IAV infection can 
improve MRSA clearance by increasing macrophage bacterial phagocytosis, 
intracellular killing, and increasing production of nitric oxide. This also suggests that 
TLR9 antagonism may be an effective therapeutic for MRSA complicated influenza 
infections. However, care should be taken to know the nature of the secondary 
infection as TLR9 regulates MRSA, but not SPS3 coinfection. Future work will be 
focused on elucidating the mechanism(s) of influenza-induced upregulation of TLR9. 
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Figure 6-12: Immune cell profiles in TLR9-/- mice post-IAV infection. Absolute number of lung immune cells post- 
lung collagenase digestion in BALB/c and TLR9-/- mice that were infected with IAV (100 PFUs, H1N1) for 5 days. Total 
lung cells counted by hemocytometer and immune cell quantification was done by flow cytometry; gating was as follows: 
neutrophils (CD45+,CD11b+,MHCII-,Ly6G+); conventional dendritic cells (CD45+,CD11c+,MHCII+,CD64-); AMs 
(CD45+,CD11c+,Siglec F+,CD64+); interstitial Macs (CD45+,CD11b+,MHCII+,Siglec F-, CD64+); B cells (CD45+CD90.2- 
CD19+); CD4+ T cells (CD45+CD90.2+CD4+); CD8+ T cells (CD45+CD90.2+CD4-);  Th1 (CD45+CD90.2+CD4+,IFN-γ+); 
Th2 (CD45+CD90.2+CD4+IL-4+); Th17 (CD45+CD90.2+CD4+IL-17a+); Tregs (CD45+CD90.2+CD4+Foxp3+). Statistics are 
student T test between comparative groups; ns= non-significant. 
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